beta

ALNY

Alnylam Pharmaceuticals Inc.

Alny

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-07-2018 08-02-2018 05-03-2018 after market close 02-08-2018 11-07-2017 after market close 08-09-2017 after market close 05-05-2017
Actual EPS -2.43 -1.83 -1.41 -1.48 -1.34 -1.34 -1.25
Consensus EPS -2.02 -1.74 -1.48 -1.38 -1.23 -1.45 -1.22
Estimated EPS -2.02 -1.74 -1.48 -1.38 -1.23 -1.45 -1.22
Number of Estimates 5 4 6 8 9 8 6
EPS Surprise -$0.41 -$0.09 $0.07 -$0.10 -$0.11 $0.11 -$0.03

Stats

Summary

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Market Cap: 13.3 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.alnylam.com

Shares Outstanding: 99.2 Million

Float: 98.7 Million

Dividend: 0.0 (0.0%)

Beta: 2.669606

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 5.88 Million

Ethical Flags

Animal testing

Longest drawdown: 603 trading days

From: 2015-06-22 To: 2017-11-09

Lowest Point:

Alnylam settles litigation with Silence Therapeutics

via: SeekingAlpha at 2018-12-10 06:52:45:000

Alnylam Pharmaceuticals(NASDAQ: ALNY ) has resolved all litigation worldwide with Silence Therapeutics, therebyavoiding the costs and distraction associated with continued litigation in multiple countries. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, … read more...

Alnylam settles litigation with Silence Therapeutics

via: SeekingAlpha at 2018-12-10 06:52:45:000

Alnylam Pharmaceuticals(NASDAQ: ALNY ) has resolved all litigation worldwide with Silence Therapeutics, therebyavoiding the costs and distraction associated with continued litigation in multiple countries. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, … read more...

Alnylam Announces Settlement of Litigation with Silence Therapeutics

via: Business Wire at 2018-12-10 02:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has resolved all litigation worldwide with Silence Therapeutics. The settlement allows Alnylam to avoid the costs and distraction associated with continued litigation in multip… read more...

Alnylam Announces Settlement of Litigation with Silence Therapeutics

via: Business Wire at 2018-12-10 02:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has resolved all litigation worldwide with Silence Therapeutics. The settlement allows Alnylam to avoid the costs and distraction associated with continued litigation in multip… read more...

Alnylam Pharmaceuticals Tries To Rally The Troops With A Blizzard Of New R&D Candidates

via: SeekingAlpha at 2018-12-08 00:23:30:000

There are two criticisms youll never read about Alnylam ( ALNY ) that management is insufficiently promotional of the company, and that it doesnt have enough pipeline candidates/ideas. Always a company with many irons in the fire, Alnylam hosted an R&D day Thursd… read more...

Alnylam Pharmaceuticals Tries To Rally The Troops With A Blizzard Of New R&D Candidates

via: SeekingAlpha at 2018-12-08 00:23:30:000

There are two criticisms youll never read about Alnylam ( ALNY ) that management is insufficiently promotional of the company, and that it doesnt have enough pipeline candidates/ideas. Always a company with many irons in the fire, Alnylam hosted an R&D day Thursd… read more...

Moderna IPO: Very Expensive

via: SeekingAlpha at 2018-12-06 09:02:42:000

Moderna (MRNA) seems too expensive with an enterprise value of $7.461 billion. Other competitors report enterprise value of $7.61-$10 billion with a more advanced stage of development. Competitors at an early stage of development, like Moderna, trade with an enterprise value of $1.28 billion. … read more...

Moderna IPO: Very Expensive

via: SeekingAlpha at 2018-12-06 09:02:42:000

Moderna (MRNA) seems too expensive with an enterprise value of $7.461 billion. Other competitors report enterprise value of $7.61-$10 billion with a more advanced stage of development. Competitors at an early stage of development, like Moderna, trade with an enterprise value of $1.28 billion. … read more...

Alnylam updates on pipeline at R&D Day

via: SeekingAlpha at 2018-12-06 08:57:53:000

At its R&D Day in New York today, Alnylam Pharmaceuticals (NASDAQ: ALNY ) will discuss its pipeline objectives and patisiran commercial plan for next year. Highlights: More news on: Alnylam Pharmaceuticals, Inc., The Medicines Company, Healthcare stocks news, Read more … read more...

Alnylam updates on pipeline at R&D Day

via: SeekingAlpha at 2018-12-06 08:57:53:000

At its R&D Day in New York today, Alnylam Pharmaceuticals (NASDAQ: ALNY ) will discuss its pipeline objectives and patisiran commercial plan for next year. Highlights: More news on: Alnylam Pharmaceuticals, Inc., The Medicines Company, Healthcare stocks news, Read more … read more...

Alnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day

via: Business Wire at 2018-12-06 07:00:00:000

In 2019, Alnylam Will Continue ONPATTRO Global Launch and Advance Late-Stage Pipeline of Wholly Owned and Partnered Programs with: Five Phase 3 Programs; Three Phase 3 Program Readouts; and Two New Drug Application (NDA) Filings Initiates Rolling Subm… read more...

Alnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day

via: Business Wire at 2018-12-06 07:00:00:000

In 2019, Alnylam Will Continue ONPATTRO Global Launch and Advance Late-Stage Pipeline of Wholly Owned and Partnered Programs with: Five Phase 3 Programs; Three Phase 3 Program Readouts; and Two New Drug Application (NDA) Filings Initiates Rolling Subm… read more...

Alnylam to Webcast R&D Day

via: Business Wire at 2018-11-29 08:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the Companys website, www.alnylam.com , on the morning of December 6, 2018… read more...

Alnylam to Webcast R&D Day

via: Business Wire at 2018-11-29 08:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the Companys website, www.alnylam.com , on the morning of December 6, 2018… read more...

Alnylam to Webcast R&D Day

via: Business Wire at 2018-11-29 08:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the Companys website, www.alnylam.com , on the morning of December 6, 2018… read more...

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-26 08:00:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of t… read more...

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-26 08:00:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of t… read more...

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-26 08:00:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of t… read more...

Vir Bio launches Phase 1/2 study of RNAi therapeutic for HBV

via: SeekingAlpha at 2018-11-26 07:50:19:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that licensee Vir Biotechnology has initiated a Phase 1/2 clinical trial evaluating RNAi therapeutic VIR-2218 for the treatment of chronic hepatitis B virus (HBV) infection. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks… read more...

Vir Bio launches Phase 1/2 study of RNAi therapeutic for HBV

via: SeekingAlpha at 2018-11-26 07:50:19:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that licensee Vir Biotechnology has initiated a Phase 1/2 clinical trial evaluating RNAi therapeutic VIR-2218 for the treatment of chronic hepatitis B virus (HBV) infection. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks… read more...

Vir Bio launches Phase 1/2 study of RNAi therapeutic for HBV

via: SeekingAlpha at 2018-11-26 07:50:19:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that licensee Vir Biotechnology has initiated a Phase 1/2 clinical trial evaluating RNAi therapeutic VIR-2218 for the treatment of chronic hepatitis B virus (HBV) infection. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks… read more...

Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218

via: Business Wire at 2018-11-26 07:00:00:000

-- Novel investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection -- Subject dosing commenced Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, inve… read more...

Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218

via: Business Wire at 2018-11-26 07:00:00:000

-- Novel investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection -- Subject dosing commenced Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, inve… read more...

Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218

via: Business Wire at 2018-11-26 07:00:00:000

-- Novel investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection -- Subject dosing commenced Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, inve… read more...

Viking Therapeutics Won't Live Up To The Hype

via: SeekingAlpha at 2018-11-26 05:00:00:000

NASH an introduction Fatty deposits and mild fibrosis in non-alcoholic fatty liver disease. Source NASH short for non-alcoholic steatohepatitis has been a magnet for biotech investors over the past few years. NASH designates the most severe form of non-alc… read more...

Viking Therapeutics Won't Live Up To The Hype

via: SeekingAlpha at 2018-11-26 05:00:00:000

NASH an introduction Fatty deposits and mild fibrosis in non-alcoholic fatty liver disease. Source NASH short for non-alcoholic steatohepatitis has been a magnet for biotech investors over the past few years. NASH designates the most severe form of non-alc… read more...

Viking Therapeutics Won't Live Up To The Hype

via: SeekingAlpha at 2018-11-26 05:00:00:000

NASH an introduction Fatty deposits and mild fibrosis in non-alcoholic fatty liver disease. Source NASH short for non-alcoholic steatohepatitis has been a magnet for biotech investors over the past few years. NASH designates the most severe form of non-alc… read more...

DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-23 10:30:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of t… read more...

DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-23 10:30:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of t… read more...

DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-23 10:30:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of t… read more...

CURRENT SHAREHOLDERS: Zamansky LLC Investigates Alnylam Pharmaceuticals (ALNY) for Potential Breaches of Fiduciary Duties

via: Business Wire at 2018-11-21 16:35:00:000

Zamansky LLC announces that it is investigating Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NasdaqGS: ALNY) for potential breaches of fiduciary duties by its senior officers and board of directors. If you are a shareholder of Alnylam who still hold… read more...

CURRENT SHAREHOLDERS: Zamansky LLC Investigates Alnylam Pharmaceuticals (ALNY) for Potential Breaches of Fiduciary Duties

via: Business Wire at 2018-11-21 16:35:00:000

Zamansky LLC announces that it is investigating Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NasdaqGS: ALNY) for potential breaches of fiduciary duties by its senior officers and board of directors. If you are a shareholder of Alnylam who still hold… read more...

Alnylam to Webcast Presentations at Upcoming Investor Conferences

via: Business Wire at 2018-11-21 08:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 30 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 10:00 am ET at the Lo… read more...

Alnylam to Webcast Presentations at Upcoming Investor Conferences

via: Business Wire at 2018-11-21 08:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 30 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 10:00 am ET at the Lo… read more...

A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed

via: SeekingAlpha at 2018-11-20 05:21:30:000

Theres not much any company can do about a bad tape, but Alnylam ( ALNY ) has seen sentiment sour pretty sharply since late 2017 despite the approval and launch of its first drug Onpattro. Between worries about greater competition (moreso from Pfizer ( PFE ) than Ionis ( IONS )/ … read more...

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.

via: Business Wire at 2018-11-19 13:12:00:000

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) (Alnylam) investors that a securities fraud class action lawsuit has been filed on behalf of purchasers of Alnylam securities between February 15, 2018 and September … read more...

Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important November 26 Deadline in Class Action - ALNY

via: PR Newswire at 2018-11-15 16:56:00:000

NEW YORK , Nov. 15, 2018 /PRNewswire/ --Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018 , inclusive (the "Class Period") of the important Nov… read more...

Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important November 26 Deadline in Class Action - ALNY

via: PR Newswire at 2018-11-15 16:56:00:000

NEW YORK , Nov. 15, 2018 /PRNewswire/ --Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018 , inclusive (the "Class Period") of the important Nov… read more...

Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important November 26 Deadline in Class Action - ALNY

via: PR Newswire at 2018-11-15 16:56:00:000

NEW YORK , Nov. 15, 2018 /PRNewswire/ --Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018 , inclusive (the "Class Period") of the important Nov… read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Alnylam's givosiran shows durable effect in hepatic porphyria study

via: SeekingAlpha at 2018-11-09 13:19:22:000

At data cutoff, the mean time on treatment was 13.6 months. Monthly dosing produced annualized attack rate (AAR) by 93% and annualized hemin use by 94% (hemin for injection, branded as Panhematin by Recordati Rare Diseases, works by lowering the production of certain enzymes in the body th… read more...

Alnylam's givosiran shows durable effect in hepatic porphyria study

via: SeekingAlpha at 2018-11-09 13:19:22:000

At data cutoff, the mean time on treatment was 13.6 months. Monthly dosing produced annualized attack rate (AAR) by 93% and annualized hemin use by 94% (hemin for injection, branded as Panhematin by Recordati Rare Diseases, works by lowering the production of certain enzymes in the body th… read more...

Alnylam's givosiran shows durable effect in hepatic porphyria study

via: SeekingAlpha at 2018-11-09 13:19:22:000

At data cutoff, the mean time on treatment was 13.6 months. Monthly dosing produced annualized attack rate (AAR) by 93% and annualized hemin use by 94% (hemin for injection, branded as Panhematin by Recordati Rare Diseases, works by lowering the production of certain enzymes in the body th… read more...

Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

via: Business Wire at 2018-11-09 08:00:00:000

Givosiran Demonstrated Sustained Clinical Activity, with an Over 90 Percent Decrease in Mean Annualized Porphyria Attack Rate, Relative to Baseline Safety Profile Encouraging with up to 25 Months of Treatment Alnylam Pharmaceuticals, Inc. &#xA… read more...

Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

via: Business Wire at 2018-11-09 08:00:00:000

Givosiran Demonstrated Sustained Clinical Activity, with an Over 90 Percent Decrease in Mean Annualized Porphyria Attack Rate, Relative to Baseline Safety Profile Encouraging with up to 25 Months of Treatment Alnylam Pharmaceuticals, Inc. &#xA… read more...

Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

via: Business Wire at 2018-11-09 08:00:00:000

Givosiran Demonstrated Sustained Clinical Activity, with an Over 90 Percent Decrease in Mean Annualized Porphyria Attack Rate, Relative to Baseline Safety Profile Encouraging with up to 25 Months of Treatment Alnylam Pharmaceuticals, Inc. &#xA… read more...

Alnylam Pharmaceuticals (ALNY) Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-07 20:49:36:000

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2018 Earnings Call November 07, 2018 8:30 am ET Executives Christine Regan Lindenboom - Alnylam Pharmaceuticals, Inc. John M. Maraganore - Alnylam Pharmaceuticals, Inc. Akshay K. Vaishnaw - Alnylam Pharmaceuticals, Inc. Barry E. Greene - … read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALNY

via: PR Newswire at 2018-11-07 17:51:00:000

NEW YORK , Nov. 7, 2018 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY) and certain of its officers. The class action, filed in United States Distr… read more...

Alnylam Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-11-07 10:18:30:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more … read more...

Alnylam Pharmaceuticals Q3 revenues down 88%

via: SeekingAlpha at 2018-11-07 08:41:26:000

Alnylam Pharmaceuticals ( ALNY ) Q3 results : Revenues: $2.1M (-87.7%). More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Alnylam Pharmaceuticals beats by $0.42, misses on revenue

via: SeekingAlpha at 2018-11-07 08:01:45:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q3 Non-GAAP EPS of -$1.56 beats by $0.42 ; GAAP EPS of -$2.43 misses by $0.45 . More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity

via: Business Wire at 2018-11-07 08:00:00:000

Obtained FDA and EMA Approvals of ONPATTRO (patisiran) the First-Ever RNAi Therapeutic and Launched in U.S. and EU Received 125 U.S. Patient Start Forms in First Seven Weeks of ONPATTRO Launch Reported Positive… read more...

Notable earnings before Wednesday's open

via: SeekingAlpha at 2018-11-06 17:30:01:000

ALNY , AMRX , ANDX , ASC , AVA , CARS , CDK , CLNY , CNDT , CNHI , COTY , CRL , CSTE , DF , DISH , DLPH , ENBL , FOXA , GEO , GIB , GRPN , HUM , HZNP , KELYA , KORS , MDP , MGLN , MIDD , MNTA , NSIT , ODP , PFGC , RCM , RDWR , ROK , SBGI , SMG , SMI , … read more...

Alnylam to Webcast Presentations at Upcoming Investor Conferences

via: Business Wire at 2018-11-06 16:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 10:15 am ET at the Lotte New York Pal… read more...

It's Time To Buy Microsoft - Cramer's Lightning Round (11/2/18)

via: SeekingAlpha at 2018-11-05 06:37:07:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, November 2 . Bullish Calls Microsoft (MSFT): They reported a good quarter and the stock went down due to a selloff in tech. It's time to buy. ResMed (RMD): CEO Mark Farrell is doing a good job… read more...

Cramer's lightning round: It's time to buy the stock of Microsoft

via: CNBC at 2018-11-02 18:47:00:000

No summary available. read more...

Cramer's lightning round: It's time to buy the stock of Microsoft

via: CNBC at 2018-11-02 18:47:00:000

No summary available. read more...

Cramer's lightning round: It's time to buy the stock of Microsoft

via: CNBC at 2018-11-02 18:47:00:000

No summary available. read more...

Alnylam to Webcast Conference Call Discussing Third Quarter 2018 Financial Results

via: Business Wire at 2018-10-30 16:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2018 on Wednesday, November 7, 2018, before the U.S. financial markets open. Management will provide an … read more...

Alnylam to Webcast Conference Call Discussing Third Quarter 2018 Financial Results

via: Business Wire at 2018-10-30 16:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2018 on Wednesday, November 7, 2018, before the U.S. financial markets open. Management will provide an … read more...

Alnylam to Webcast Conference Call Discussing Third Quarter 2018 Financial Results

via: Business Wire at 2018-10-30 16:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2018 on Wednesday, November 7, 2018, before the U.S. financial markets open. Management will provide an … read more...

Lifshitz & Miller LLP Announces Investigation of Alnylam Pharmaceuticals, Inc., Campbell Soup Company, Fanhua Inc., Hasbro, Inc., OPKO Health, Inc., Pretium Resources, Inc., Rowan Companies PLC and SodaStream International Ltd.

via: PR Newswire at 2018-10-30 15:21:00:000

NEW YORK , Oct. 30, 2018 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (ALNY) Lifshitz & Miller announces investigation into possible securities laws violations in connection with FDA reviewers having concerns of a "potential platform safety risk" with the ONPATTRO trials… read more...

Lifshitz & Miller LLP Announces Investigation of Alnylam Pharmaceuticals, Inc., Campbell Soup Company, Fanhua Inc., Hasbro, Inc., OPKO Health, Inc., Pretium Resources, Inc., Rowan Companies PLC and SodaStream International Ltd.

via: PR Newswire at 2018-10-30 15:21:00:000

NEW YORK , Oct. 30, 2018 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (ALNY) Lifshitz & Miller announces investigation into possible securities laws violations in connection with FDA reviewers having concerns of a "potential platform safety risk" with the ONPATTRO trials… read more...

Lifshitz & Miller LLP Announces Investigation of Alnylam Pharmaceuticals, Inc., Campbell Soup Company, Fanhua Inc., Hasbro, Inc., OPKO Health, Inc., Pretium Resources, Inc., Rowan Companies PLC and SodaStream International Ltd.

via: PR Newswire at 2018-10-30 15:21:00:000

NEW YORK , Oct. 30, 2018 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (ALNY) Lifshitz & Miller announces investigation into possible securities laws violations in connection with FDA reviewers having concerns of a "potential platform safety risk" with the ONPATTRO trials… read more...

Dicerna Pharmaceuticals Keeps The Deals Rolling In On The Promise Of Its Groundbreaking GalXC RNAi Technology

via: SeekingAlpha at 2018-10-30 09:54:50:000

Recently, Dicerna Pharmaceuticals ( DRNA ) announced a partnership with Eli Lilly ( LLY ) which amounts to an upfront payment and an equity stake . This is just one of the most recent validations of Dicerna's GalXC technology. Just this past week, Dicerna garnered another deal with Ale… read more...

Dicerna Pharmaceuticals Keeps The Deals Rolling In On The Promise Of Its Groundbreaking GalXC RNAi Technology

via: SeekingAlpha at 2018-10-30 09:54:50:000

Recently, Dicerna Pharmaceuticals ( DRNA ) announced a partnership with Eli Lilly ( LLY ) which amounts to an upfront payment and an equity stake . This is just one of the most recent validations of Dicerna's GalXC technology. Just this past week, Dicerna garnered another deal with Ale… read more...

Dicerna Pharmaceuticals Keeps The Deals Rolling In On The Promise Of Its Groundbreaking GalXC RNAi Technology

via: SeekingAlpha at 2018-10-30 09:54:50:000

Recently, Dicerna Pharmaceuticals ( DRNA ) announced a partnership with Eli Lilly ( LLY ) which amounts to an upfront payment and an equity stake . This is just one of the most recent validations of Dicerna's GalXC technology. Just this past week, Dicerna garnered another deal with Ale… read more...

Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria

via: PR Newswire at 2018-10-29 07:30:00:000

SAN FRANCISCO , Oct. 29, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced today it has expanded its partnership with Alnylam Pharmaceuticals , the leading RNAi therapeutics company, to provide genetic testing at no cos… read more...

Alnylam to offer free genetic testing/counseling for potential candidates in lumasiran studies

via: SeekingAlpha at 2018-10-25 13:56:26:000

Alnylam Pharmaceuticals ( ALNY +6.4% ) has expanded it Alnylam Act program to include free-of-charge third-party genetic testing and counseling for adults and children who may have AGXT mutations associated with primary hyperoxaluria type 1 (PH1). Identified patients may be suitable cand… read more...

Alnylam to offer free genetic testing/counseling for potential candidates in lumasiran studies

via: SeekingAlpha at 2018-10-25 13:56:26:000

Alnylam Pharmaceuticals ( ALNY +6.4% ) has expanded it Alnylam Act program to include free-of-charge third-party genetic testing and counseling for adults and children who may have AGXT mutations associated with primary hyperoxaluria type 1 (PH1). Identified patients may be suitable cand… read more...

Alnylam to offer free genetic testing/counseling for potential candidates in lumasiran studies

via: SeekingAlpha at 2018-10-25 13:56:26:000

Alnylam Pharmaceuticals ( ALNY +6.4% ) has expanded it Alnylam Act program to include free-of-charge third-party genetic testing and counseling for adults and children who may have AGXT mutations associated with primary hyperoxaluria type 1 (PH1). Identified patients may be suitable cand… read more...

Alnylam Expands Alnylam Act® Program to Improve Diagnosis of Primary Hyperoxaluria Type 1 (PH1) and Aligns with FDA on Trial Design for ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran

via: Business Wire at 2018-10-25 13:00:00:000

Alnylam Act to Include No-Charge Third-Party Genetic Testing and Counseling for Adults and Children at Risk for PH1 ILLUMINATE-B to Evaluate Safety and Efficacy of Lumasiran in PH1 Patients Under Six Years of Age Company Reports on New … read more...

Alnylam Expands Alnylam Act® Program to Improve Diagnosis of Primary Hyperoxaluria Type 1 (PH1) and Aligns with FDA on Trial Design for ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran

via: Business Wire at 2018-10-25 13:00:00:000

Alnylam Act to Include No-Charge Third-Party Genetic Testing and Counseling for Adults and Children at Risk for PH1 ILLUMINATE-B to Evaluate Safety and Efficacy of Lumasiran in PH1 Patients Under Six Years of Age Company Reports on New … read more...

Alnylam Expands Alnylam Act® Program to Improve Diagnosis of Primary Hyperoxaluria Type 1 (PH1) and Aligns with FDA on Trial Design for ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran

via: Business Wire at 2018-10-25 13:00:00:000

Alnylam Act to Include No-Charge Third-Party Genetic Testing and Counseling for Adults and Children at Risk for PH1 ILLUMINATE-B to Evaluate Safety and Efficacy of Lumasiran in PH1 Patients Under Six Years of Age Company Reports on New … read more...

ALNY NOTICE ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc., Important Deadline in Class Action - ALNY

via: PR Newswire at 2018-10-24 18:30:00:000

NEW YORK , Oct. 24, 2018 /PRNewswire/ --Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018 , … read more...

Alnylam Announces Advocacy for Impact Grants to Inspire Unique Solutions that Address Unmet Needs Affecting the Rare Disease Community

via: Business Wire at 2018-10-24 07:00:00:000

Alnylams Advocacy for Impact Grants Will Fund New Projects of Up to $50,000 to Patient Advocacy Groups that Impact the ATTR Amyloidosis, Acute Hepatic Porphyrias and/or Primary Hyperoxaluria Type 1 Communities Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY),… read more...

Biotechs set for down gap at open

via: SeekingAlpha at 2018-10-23 09:25:19:000

The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is down 2% premarket on light volume, continuing its 2% slide yesterday. More news on: SPDR Biotech ETF, Amgen Inc., Biogen Inc., Healthcare stocks news, Stocks on the move, News on ETFs, Read more … read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

via: Business Wire at 2018-10-22 16:47:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ:ALNY) of the November 26, 2018 deadline to seek the role of lead plaintiff in a federal securities class actio… read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Alnylam Pharmaceuticals, Inc. to Contact the Firm

via: Business Wire at 2018-10-19 14:57:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ:ALNY) of the November 26, 2018 deadline to seek the role of lead plaintiff in a federal securities class actio… read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Alnylam Pharmaceuticals, Inc. to Contact the Firm

via: Business Wire at 2018-10-19 14:57:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ:ALNY) of the November 26, 2018 deadline to seek the role of lead plaintiff in a federal securities class actio… read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Alnylam Pharmaceuticals, Inc. to Contact the Firm

via: Business Wire at 2018-10-19 14:57:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ:ALNY) of the November 26, 2018 deadline to seek the role of lead plaintiff in a federal securities class actio… read more...

Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran

via: Business Wire at 2018-10-15 07:00:00:000

Topline Results on Primary Endpoint of Annualized Attack Rate Expected in Early 2019 Company Plans to Initiate a Rolling Submission of an NDA in 2018 with Addition of Full Clinical Results in Mid-2019 in Support of a Full Approval Alnylam Phar… read more...

Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran

via: Business Wire at 2018-10-15 07:00:00:000

Topline Results on Primary Endpoint of Annualized Attack Rate Expected in Early 2019 Company Plans to Initiate a Rolling Submission of an NDA in 2018 with Addition of Full Clinical Results in Mid-2019 in Support of a Full Approval Alnylam Phar… read more...

Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran

via: Business Wire at 2018-10-15 07:00:00:000

Topline Results on Primary Endpoint of Annualized Attack Rate Expected in Early 2019 Company Plans to Initiate a Rolling Submission of an NDA in 2018 with Addition of Full Clinical Results in Mid-2019 in Support of a Full Approval Alnylam Phar… read more...

Catalyst Biosciences: Rare Risk/Reward Opportunity

via: SeekingAlpha at 2018-10-14 22:32:37:000

General Overview of Pipeline Catalyst Biosciences ( CBIO ) is a clinical-stage biopharmaceutical company focused on developing hemostasis treatments. Since the company became public after a merger deal with Targacept, it is known that Catalyst has engineered three therapeutic candidates … read more...

Catalyst Biosciences: Rare Risk/Reward Opportunity

via: SeekingAlpha at 2018-10-14 22:32:37:000

General Overview of Pipeline Catalyst Biosciences ( CBIO ) is a clinical-stage biopharmaceutical company focused on developing hemostasis treatments. Since the company became public after a merger deal with Targacept, it is known that Catalyst has engineered three therapeutic candidates … read more...

Catalyst Biosciences: Rare Risk/Reward Opportunity

via: SeekingAlpha at 2018-10-14 22:32:37:000

General Overview of Pipeline Catalyst Biosciences ( CBIO ) is a clinical-stage biopharmaceutical company focused on developing hemostasis treatments. Since the company became public after a merger deal with Targacept, it is known that Catalyst has engineered three therapeutic candidates … read more...

Alnylam Appoints Dr. Margaret Hamburg to Board of Directors

via: Business Wire at 2018-10-10 07:00:00:000

Dr. Hamburg is Former FDA Commissioner and Internationally Recognized as a Distinguished Authority in Medicine, Regulatory Science and Public Health Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the appointment … read more...

Alnylam Appoints Dr. Margaret Hamburg to Board of Directors

via: Business Wire at 2018-10-10 07:00:00:000

Dr. Hamburg is Former FDA Commissioner and Internationally Recognized as a Distinguished Authority in Medicine, Regulatory Science and Public Health Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the appointment … read more...

Alnylam Appoints Dr. Margaret Hamburg to Board of Directors

via: Business Wire at 2018-10-10 07:00:00:000

Dr. Hamburg is Former FDA Commissioner and Internationally Recognized as a Distinguished Authority in Medicine, Regulatory Science and Public Health Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the appointment … read more...

Arbutus Biopharma: The Good, The Bad, And The Ugly

via: SeekingAlpha at 2018-10-09 11:25:50:000

Introduction Arbutus Biopharma ( ABUS ) is one of the many biotech companies focused on the research and development of Hepatitis B therapeutics. What helps make the company stand out from the crowd is its diverse pipeline and financial situation. The company has made great strides in deve… read more...

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.

via: Business Wire at 2018-10-09 09:26:00:000

The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) (Alnylam) on behalf of purchasers of Alnylam securities between February 15, 2018 and Se… read more...

Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders in Recently Filed Class Action

via: Business Wire at 2018-10-08 15:56:00:000

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between February 15, 2018 … read more...

FDA nod for Akcea's intersen fails to lift shares, down 16%

via: SeekingAlpha at 2018-10-08 15:43:40:000

Ionis Pharmaceuticals ( IONS -8.5% ) and affiliate Akcea Therapeutics ( AKCA -15.7% ) slump on increased volume following FDA approval for TEGSEDI (inotersen) for hATTR. Normally, a bullish event but investors appear concerned about its ability to compete with Alnylam Pharmaceuticals' ( … read more...

Lilly Surges On Pipeline News: Analysis And Trading Thoughts

via: SeekingAlpha at 2018-10-08 14:49:36:000

Introduction Eli Lilly ( LLY ) has been on a roll, powered by some fast-growing young products, some resiliency of its older stalwarts, and a promising pipeline. See p. 12 of LLY's Q2 detailed earnings release for a list of sales and yoy growth rates for these drugs. The reason I have rent… read more...

ALNY LOSS NOTICE: Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important Deadline in Class Action - ALNY

via: Business Wire at 2018-10-06 15:00:00:000

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018, inclusive (the Class Period) of the important November 26, 2018 lead plaintiff deadline i… read more...

ALNY LOSS NOTICE: Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important Deadline in Class Action - ALNY

via: Business Wire at 2018-10-06 15:00:00:000

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018, inclusive (the Class Period) of the important November 26, 2018 lead plaintiff deadline i… read more...

FDA OKs Akcea's inotersen for hATTR

via: SeekingAlpha at 2018-10-06 14:12:09:000

The FDA approves Akcea Therapeutics' (NASDAQ: AKCA ) TEGSEDI (inotersen) for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR). More news on: Akcea Therapeutics, Express Scripts, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news,… read more...

FDA OKs Akcea's inotersen for hATTR

via: SeekingAlpha at 2018-10-06 14:12:09:000

The FDA approves Akcea Therapeutics' (NASDAQ: AKCA ) TEGSEDI (inotersen) for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR). More news on: Akcea Therapeutics, Express Scripts, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news,… read more...

Alnylam reports positive results from Phase 1/2 study of lumasiran in patients with PH1

via: SeekingAlpha at 2018-10-04 07:42:12:000

Alnylam Pharmaceuticals(NASDAQ: ALNY ) reports updated positive results from its Phase 1/2 clinical study of lumasiran, an RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1 (PH1). More news on: Alnylam Pharmaceuticals, Inc., Healthcare s… read more...

Alnylam reports positive results from Phase 1/2 study of lumasiran in patients with PH1

via: SeekingAlpha at 2018-10-04 07:42:12:000

Alnylam Pharmaceuticals(NASDAQ: ALNY ) reports updated positive results from its Phase 1/2 clinical study of lumasiran, an RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1 (PH1). More news on: Alnylam Pharmaceuticals, Inc., Healthcare s… read more...

Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1

via: Business Wire at 2018-10-04 07:00:00:000

Lumasiran Treatment Resulted in 75 Percent Mean Maximal Reduction in Urinary Oxalate Relative to Baseline, with 100 Percent of Patients Achieving Levels of Urinary Oxalate Less Than 1.5 Times Upper Limit of Normal Lumasiran Shows Encouraging Safety Profile wi… read more...

Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1

via: Business Wire at 2018-10-04 07:00:00:000

Lumasiran Treatment Resulted in 75 Percent Mean Maximal Reduction in Urinary Oxalate Relative to Baseline, with 100 Percent of Patients Achieving Levels of Urinary Oxalate Less Than 1.5 Times Upper Limit of Normal Lumasiran Shows Encouraging Safety Profile wi… read more...

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Alnylam Pharmaceuticals, Inc. - ALNY

via: PR Newswire at 2018-10-03 14:30:00:000

RADNOR, Pa. , Oct. 3, 2018 /PRNewswire/ --The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) ("Alnylam") on behalf of purchasers of Alnylam securitie… read more...

Alnylam Submits Clinical Trial Authorization (CTA) Application for ALN-AAT02, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

via: Business Wire at 2018-10-03 07:00:00:000

ALN-AAT02 is the First Investigational RNAi Therapeutic to Utilize Alnylams Enhanced Stabilization Chemistry Plus (ESC+) GalNAc-Conjugate Technology Company Expects to Initiate Phase 1/2 Study by Year-End 2018 Alnylam Pharmaceuticals, … read more...

Alnylam Launches ONPATTRO(TM) (patisiran), the First-Ever RNAi Therapeutic, in Germany

via: Business Wire at 2018-10-02 16:00:00:000

ONPATTRO Indicated for Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR Amyloidosis) in Adults with Stage 1 or Stage 2 Polyneuropathy Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics com… read more...

Alnylam Reports New Platform Innovations for RNAi Therapeutics at the Oligonucleotide Therapeutics Society 2018 Annual Meeting

via: Business Wire at 2018-10-02 14:50:00:000

Achieves Robust and Durable Target Gene Silencing with Central Nervous System Delivery of Novel siRNA Conjugates in Non-Human Primates Extends Progress on Extrahepatic Delivery with Ocular Disease Targets Alnylam Pharmaceuticals, Inc. &#xA0… read more...

NASH players under pressure following Liver Meeting abstract drop

via: SeekingAlpha at 2018-10-02 12:50:37:000

Biotechs developing treatments for nonalcoholic steatohepatitis (NASH) and other fatty liver diseases are seeing some action following the release of abstracts for November's Liver Meeting in San Francisco. More news on: NGM Biopharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals… read more...

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-10-01 19:49:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of the Securities… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-01 08:48:56:000

Neon Therapeutics (NASDAQ: NTGN ) initiated with Buy rating and $20 (134% upside) price target at Ladenburg Thalmann. More news on: Neon Therapeutics, Incyte Corporation, Intercept Pharmaceuticals, Healthcare stocks news, Stocks on the move, , Read more … read more...

The Medicines Company's late-stage inclisiran studies to continue as planned

via: SeekingAlpha at 2018-10-01 08:08:01:000

Based on the fourth planned IDMC review of three ongoing Phase 3 clinical trials, ORION-9, -10 and -11, evaluating The Medicines Company's (NASDAQ: MDCO ) inclisiran in patients with inherited high levels of cholesterol, the studies will continue as planned . Topline data should be availabl… read more...

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-09-28 11:34:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of the Securities… read more...

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-09-28 11:34:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of the Securities… read more...

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-09-28 11:34:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of the Securities… read more...

Alnylam submits Onpattro marketing application in Japan

via: SeekingAlpha at 2018-09-28 07:20:04:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) has filed a marketing application in Japan seeking approval for ONPATTRO (patisiran sodium) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis, an Orphan Drug indication there. More news on: Alnylam Pharmaceuticals, Inc., He… read more...

Alnylam submits Onpattro marketing application in Japan

via: SeekingAlpha at 2018-09-28 07:20:04:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) has filed a marketing application in Japan seeking approval for ONPATTRO (patisiran sodium) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis, an Orphan Drug indication there. More news on: Alnylam Pharmaceuticals, Inc., He… read more...

Alnylam submits Onpattro marketing application in Japan

via: SeekingAlpha at 2018-09-28 07:20:04:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) has filed a marketing application in Japan seeking approval for ONPATTRO (patisiran sodium) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis, an Orphan Drug indication there. More news on: Alnylam Pharmaceuticals, Inc., He… read more...

Alnylam Announces Submission of New Drug Application in Japan for ONPATTRO(TM) (patisiran sodium) for Treatment of Hereditary ATTR Amyloidosis

via: Business Wire at 2018-09-28 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has submitted a New Drug Application (NDA) to Japans Pharmaceuticals and Medical Devices Agency (PMDA) for approval of patisiran for the treatment of hereditary transthyreti… read more...

Alnylam Announces Submission of New Drug Application in Japan for ONPATTRO(TM) (patisiran sodium) for Treatment of Hereditary ATTR Amyloidosis

via: Business Wire at 2018-09-28 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has submitted a New Drug Application (NDA) to Japans Pharmaceuticals and Medical Devices Agency (PMDA) for approval of patisiran for the treatment of hereditary transthyreti… read more...

Alnylam Announces Submission of New Drug Application in Japan for ONPATTRO(TM) (patisiran sodium) for Treatment of Hereditary ATTR Amyloidosis

via: Business Wire at 2018-09-28 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has submitted a New Drug Application (NDA) to Japans Pharmaceuticals and Medical Devices Agency (PMDA) for approval of patisiran for the treatment of hereditary transthyreti… read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

via: PR Newswire at 2018-09-27 18:06:00:000

NEW YORK , Sept. 27, 2018 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ:ALNY) of the November 26, 2018 deadline to seek the role of lead plaintiff in a federa… read more...

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Alnylam Pharmaceuticals, Inc. Investors (ALNY)

via: Business Wire at 2018-09-27 17:00:00:000

Glancy Prongay & Murray LLP (GPM) announces an investigation on behalf of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) investors concerning the Company and its officers possible violations of federal sec… read more...

Alnylam Pharmaceuticals Could Use Some Straightforward Good News

via: SeekingAlpha at 2018-09-27 16:13:30:000

Alynlam Pharmaceuticals ( ALNY ) could really use some straightforward, clean, good news right now, as several of the companys recent positive events have been yes but situations. Todays update on givosiran in acute hepatic porphyria is a case in a po… read more...

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) and Lead Plaintiff Deadline - November 26, 2018

via: PR Newswire at 2018-09-27 15:02:00:000

NEW YORK , Sept. 27, 2018 /PRNewswire/ --Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc.("Alnylam" or the "Company") (NASDAQ: ALNY) and certain of its officers, o… read more...

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Alnylam Pharmaceuticals, Inc. Investors (ALNY)

via: Business Wire at 2018-09-27 14:44:00:000

Law Offices of Howard G. Smithannounces an investigation on behalf of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) investors concerning the Company and its officers possible violations of federal securities laws. Th… read more...

ALNYLAM CLASS ACTION LAWSUIT: BERNSTEIN LIEBHARD LLP ANNOUNCES THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ALNYLAM PHARMACEUTICALS, INC. - ALNY

via: PR Newswire at 2018-09-27 10:38:00:000

NEW YORK , Sept. 27, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, anationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Alnylam Pharmaceuticals, Inc. ("Alnylam" o… read more...

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. - ALNY

via: Business Wire at 2018-09-27 10:35:00:000

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018, inclusive (the Class Period). The law… read more...

Alnylam's givosiran shows positive effect in late-stage AHP study; U.S. marketing application planned; shares ahead 2% premarket

via: SeekingAlpha at 2018-09-27 07:41:46:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) is up 2% premarket on light volume on the heels of its announcement of positive results from a Phase 3 clinical trial, ENVISION , evaluating givosiran in patients with acute hepatic porphyria (AHP), an inherited disorder affecting the … read more...

Alnylam Announces Positive Topline Results from Interim Analysis of ENVISION Phase 3 Study of Givosiran in Patients with Acute Hepatic Porphyria

via: Business Wire at 2018-09-27 07:00:00:000

Givosiran Treatment Resulted in Significant Reduction of Urinary Aminolevulinic Acid (ALA), a Disease Biomarker Reasonably Likely to Predict Clinical Benefit Company Plans to Discuss Results with FDA Regarding a Potential NDA Filing at or Around Year-End in S… read more...

Alnylam to Webcast Presentation at the 2018 Cantor Global Healthcare Conference

via: Business Wire at 2018-09-26 08:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 9:45 am ET at the InterContinental New York Barclay Hotel in… read more...

Making Sense Of Alnylam's Valuation

via: SeekingAlpha at 2018-09-24 02:24:27:000

Company Overview Alnylam ( ALNY ) is a biopharma company developing small molecules based on RNA interference (RNAi), which is a naturally occurring biological pathway for sequence-specific silencing and regulation of gene expression. RNAi therapeutics include silencing messenger RNA that … read more...

Making Sense Of Alnylam's Valuation

via: SeekingAlpha at 2018-09-24 02:24:27:000

Company Overview Alnylam ( ALNY ) is a biopharma company developing small molecules based on RNA interference (RNAi), which is a naturally occurring biological pathway for sequence-specific silencing and regulation of gene expression. RNAi therapeutics include silencing messenger RNA that … read more...

ALNYLAM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alnylam Pharmaceuticals, Inc. To Contact The Firm

via: PR Newswire at 2018-09-20 17:21:00:000

NEW YORK , Sept. 20, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities claims against Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). If you invested in Alnylam stock or … read more...

ALNYLAM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alnylam Pharmaceuticals, Inc. To Contact The Firm

via: PR Newswire at 2018-09-20 17:21:00:000

NEW YORK , Sept. 20, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities claims against Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). If you invested in Alnylam stock or … read more...

ALNYLAM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alnylam Pharmaceuticals, Inc. To Contact The Firm

via: PR Newswire at 2018-09-20 17:21:00:000

NEW YORK , Sept. 20, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities claims against Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). If you invested in Alnylam stock or … read more...

Your Daily Pharma Scoop: Alnylam Regains, Karyopharm Positive, Teva Approved

via: SeekingAlpha at 2018-09-18 10:45:37:000

Results from an exploratory Phase 3 trial of Alnylam Pharmaceuticalss ( ALNY ) Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published in the journal Circulation . Left… read more...

Your Daily Pharma Scoop: Alnylam Regains, Karyopharm Positive, Teva Approved

via: SeekingAlpha at 2018-09-18 10:45:37:000

Results from an exploratory Phase 3 trial of Alnylam Pharmaceuticalss ( ALNY ) Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published in the journal Circulation . Left… read more...

Alnylam announces publication of data showing effect of patisiran on cardiac disease in hATTR

via: SeekingAlpha at 2018-09-14 08:01:34:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that results from exploratory cardiac assessments in the Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published online in the j… read more...

Alnylam announces publication of data showing effect of patisiran on cardiac disease in hATTR

via: SeekingAlpha at 2018-09-14 08:01:34:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that results from exploratory cardiac assessments in the Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published online in the j… read more...

Alnylam announces publication of data showing effect of patisiran on cardiac disease in hATTR

via: SeekingAlpha at 2018-09-14 08:01:34:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that results from exploratory cardiac assessments in the Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published online in the j… read more...

Alnylam announces publication of data showing effect of patisiran on cardiac disease in hATTR

via: SeekingAlpha at 2018-09-14 08:01:34:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that results from exploratory cardiac assessments in the Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published online in the j… read more...

Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran

via: Business Wire at 2018-09-14 06:00:00:000

Published Data From the APOLLO Study Show That Patisiran Improved Markers of Cardiomyopathy in Patients with Hereditary ATTR Amyloidosis with Polyneuropathy In Exploratory Post-Hoc Analysis, Reduction of All-Cause Mortality and Hospitalization Was Observed in… read more...

Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran

via: Business Wire at 2018-09-14 06:00:00:000

Published Data From the APOLLO Study Show That Patisiran Improved Markers of Cardiomyopathy in Patients with Hereditary ATTR Amyloidosis with Polyneuropathy In Exploratory Post-Hoc Analysis, Reduction of All-Cause Mortality and Hospitalization Was Observed in… read more...

Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran

via: Business Wire at 2018-09-14 06:00:00:000

Published Data From the APOLLO Study Show That Patisiran Improved Markers of Cardiomyopathy in Patients with Hereditary ATTR Amyloidosis with Polyneuropathy In Exploratory Post-Hoc Analysis, Reduction of All-Cause Mortality and Hospitalization Was Observed in… read more...

Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran

via: Business Wire at 2018-09-14 06:00:00:000

Published Data From the APOLLO Study Show That Patisiran Improved Markers of Cardiomyopathy in Patients with Hereditary ATTR Amyloidosis with Polyneuropathy In Exploratory Post-Hoc Analysis, Reduction of All-Cause Mortality and Hospitalization Was Observed in… read more...

Alnylam Investigation: Bernstein Liebhard LLP Announces Investigation Of Alnylam Pharmaceuticals, Inc. - ALNY

via: PR Newswire at 2018-09-13 15:38:00:000

NEW YORK , Sept. 13, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY) resulting from alleg… read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

via: PR Newswire at 2018-09-12 17:42:00:000

NEW YORK , Sept. 12, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com … read more...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY)

via: PR Newswire at 2018-09-12 14:14:00:000

NEW YORK , Sept. 12, 2018 /PRNewswire/ -- Attorney Advertising --Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alnylam Pharmaceuticals, Inc.("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are encouraged to obtai… read more...

Alnylam Pharmaceuticals (ALNY) ONPATTRO And Investigational ALN-TTRsc02 For The Treatment Of ATTR Amyloidosis - Slideshow

via: SeekingAlpha at 2018-09-11 13:47:25:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Alnylam: Analysts See A Comet On The Rise

via: SeekingAlpha at 2018-09-06 15:01:50:000

Biopharma company Alnylam Pharmaceuticals (NASDAQ: ALNY ) has built a brand on its innovative RNAi therapeutics. ALNYs focus: developing a pipeline of drugs designed to help transform lives of patients with rare diseases. These are the patients facing either limited treatment options- … read more...

Alnylam: Analysts See A Comet On The Rise

via: SeekingAlpha at 2018-09-06 15:01:50:000

Biopharma company Alnylam Pharmaceuticals (NASDAQ: ALNY ) has built a brand on its innovative RNAi therapeutics. ALNYs focus: developing a pipeline of drugs designed to help transform lives of patients with rare diseases. These are the patients facing either limited treatment options- … read more...

Alnylam: Analysts See A Comet On The Rise

via: SeekingAlpha at 2018-09-06 15:01:50:000

Biopharma company Alnylam Pharmaceuticals (NASDAQ: ALNY ) has built a brand on its innovative RNAi therapeutics. ALNYs focus: developing a pipeline of drugs designed to help transform lives of patients with rare diseases. These are the patients facing either limited treatment options- … read more...

A Second Look At Inotersen's Approval Potential

via: SeekingAlpha at 2018-09-04 17:46:38:000

Editor's note: Seeking Alpha is proud to welcome Chris Stang as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Last week, Io… read more...

A Second Look At Inotersen's Approval Potential

via: SeekingAlpha at 2018-09-04 17:46:38:000

Editor's note: Seeking Alpha is proud to welcome Chris Stang as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Last week, Io… read more...

Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval

via: SeekingAlpha at 2018-09-01 05:42:38:000

Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516… read more...

Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval

via: SeekingAlpha at 2018-09-01 05:42:38:000

Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516… read more...

Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval

via: SeekingAlpha at 2018-09-01 05:42:38:000

Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516… read more...

Over-Extrapolation Of Pfizer Cardiomyopathy Data Creates Buying Opportunity For Eidos

via: SeekingAlpha at 2018-08-30 10:00:06:000

Pfizer ( PFE ) just announced the results for their Phase 3 ATTR-CM trial at the ESC Congress 2018. Pfizer reported a 30% reduction in the risk of all-cause mortality and a 32% reduction in the rate of CV-related hospitalization with tafamidis compared with placebo. The data can be found in … read more...

Over-Extrapolation Of Pfizer Cardiomyopathy Data Creates Buying Opportunity For Eidos

via: SeekingAlpha at 2018-08-30 10:00:06:000

Pfizer ( PFE ) just announced the results for their Phase 3 ATTR-CM trial at the ESC Congress 2018. Pfizer reported a 30% reduction in the risk of all-cause mortality and a 32% reduction in the rate of CV-related hospitalization with tafamidis compared with placebo. The data can be found in … read more...

Alnylam's patisiran OK'd in Europe for hATTR amyoidosis

via: SeekingAlpha at 2018-08-30 07:42:54:000

The European Commission approves Alnylam Pharmaceuticals' (NASDAQ: ALNY ) ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stager 1 or stage 2 polyneuropathy. More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals,… read more...

Alnylam's patisiran OK'd in Europe for hATTR amyoidosis

via: SeekingAlpha at 2018-08-30 07:42:54:000

The European Commission approves Alnylam Pharmaceuticals' (NASDAQ: ALNY ) ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stager 1 or stage 2 polyneuropathy. More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals,… read more...

FDA OK's Bayer's Jivi for hemophilia A

via: SeekingAlpha at 2018-08-30 07:37:13:000

The FDA approves Bayer's ( OTCPK:BAYRY ) Jivi (antihemophilic factor [recombinant] PEGylated-aucl) for the routine prophylactic treatment of hemophilia A in previously treated patients at least 12 years old. More news on: Bayer A.G. ADR, Catalyst Biosciences, Inc., Sangamo Therapeutics, … read more...

FDA OK's Bayer's Jivi for hemophilia A

via: SeekingAlpha at 2018-08-30 07:37:13:000

The FDA approves Bayer's ( OTCPK:BAYRY ) Jivi (antihemophilic factor [recombinant] PEGylated-aucl) for the routine prophylactic treatment of hemophilia A in previously treated patients at least 12 years old. More news on: Bayer A.G. ADR, Catalyst Biosciences, Inc., Sangamo Therapeutics, … read more...

Alnylam Receives Approval of ONPATTRO(TM) (patisiran) in Europe

via: Business Wire at 2018-08-30 07:00:00:000

ONPATTRO Indicated for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in Adults with Stage 1 or Stage 2 Polyneuropathy First-Ever RNAi Therapeutic Approved in the European Union (EU) Alnylam Pharmace… read more...

Alnylam Receives Approval of ONPATTRO(TM) (patisiran) in Europe

via: Business Wire at 2018-08-30 07:00:00:000

ONPATTRO Indicated for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in Adults with Stage 1 or Stage 2 Polyneuropathy First-Ever RNAi Therapeutic Approved in the European Union (EU) Alnylam Pharmace… read more...

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

via: Business Wire at 2018-08-29 09:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 2018 Wells Fargo Securities Healthcare Conference on Wednesday, September 5, 2018 at 10:15 am ET at the We… read more...

Pfizer's Tafamidis Will Be Standard Of Care For A Not-So-Rare Disease

via: SeekingAlpha at 2018-08-28 14:23:45:000

Novel drugs that are shown to improve survival in patients with a lethal condition quickly become standard of care for that condition. The ATTR-ACT Study sponsored by Pfizer ( PFE ) and published in Monday's issue of NEJM includes survival curves for TTR (transthyretin-related) amyloid heart… read more...

Pfizer Achieves Success In Rare Heart Disease Study

via: SeekingAlpha at 2018-08-28 13:34:45:000

Recently, Pfizer ( PFE ) released final results from its phase 3 study treating patients with a rare heart disease known as Transthyretin cardiomyopathy (TTR-CM). The results were released at a presentation at the ESC Congress 2018. The results were positive, and now the company can expl… read more...

Approval, Labeling, Pricing, And Competitor Data All Give Alnylam Pharmaceuticals A Wild Ride

via: SeekingAlpha at 2018-08-28 12:21:20:000

Its been an interesting period of time to be an Alnylam ( ALNY ) shareholder, as the company got its first FDA approval (Onpattro), but with a narrower label than hoped and a somewhat confusing price structure. On top of that, a key potential competitor that wasnt even seen a… read more...

Midday Gainers / Losers (08/27/2018)

via: SeekingAlpha at 2018-08-27 12:48:12:000

Gainers: TIS +37% . HMNY +37% . CRON +21% . TLRY +20% . ALNY +17% . JMEI +17% . CTXR +18% . LAC +15% . KONE +14% . LEVB +13% . More news on: Orchids Paper Products Company, Helios and Matheson Analytics, Inc., Cronos Group, Inc., Stocks on the move, , … read more...

Money flow stays positive in biotechs, XBI up 6% since last week

via: SeekingAlpha at 2018-08-27 11:39:49:000

Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped 6% since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the … read more...

Sell-siders bullish on Pfizer tafamidis after release of positive data

via: SeekingAlpha at 2018-08-27 10:22:07:000

Sell-side analysts weigh in on Pfizer's ( PFE -1.9% ) Vyndaqel (tafamidis) after the company released late-stage data in patients with wild-type or variant (hereditary) transthyretin amyloid cardiomyopathy. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Eidos Therapeutics, Hea… read more...

Alnylam and Ionis up on lower perceived threat from Pfizer's tafamidis in ATTR

via: SeekingAlpha at 2018-08-27 09:44:15:000

Alnylam Pharmaceuticals ( ALNY +4.6% ) is up in early trade on the heels of Pfizer's ( PFE -0.9% ) announced late-stage data on tafamidis in transthyretin amyloid cardiomyopathy. More news on: Alnylam Pharmaceuticals, Inc., Pfizer Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks ne… read more...

Alnylam: Fully Priced, But A Future Star

via: SeekingAlpha at 2018-08-21 13:06:20:000

Investors often talk of getting in on the next big thing. But it is hard to know when a small thing will become big. I believe Alnylam ( ALNY ), which specializes in RNA based therapies, is part of a small number of biotechnology companies that will be part of a very big therapeutic space over… read more...

Alnylam: Fully Priced, But A Future Star

via: SeekingAlpha at 2018-08-21 13:06:20:000

Investors often talk of getting in on the next big thing. But it is hard to know when a small thing will become big. I believe Alnylam ( ALNY ), which specializes in RNA based therapies, is part of a small number of biotechnology companies that will be part of a very big therapeutic space over… read more...

Alnylam: Fully Priced, But A Future Star

via: SeekingAlpha at 2018-08-21 13:06:20:000

Investors often talk of getting in on the next big thing. But it is hard to know when a small thing will become big. I believe Alnylam ( ALNY ), which specializes in RNA based therapies, is part of a small number of biotechnology companies that will be part of a very big therapeutic space over… read more...

Alnylam competes enrollment in late-stage study of givosiran in AHP

via: SeekingAlpha at 2018-08-21 07:29:04:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) has completed enrollment of 94 subjects in its Phase 3 ENVISION study evaluating givosiran in patients with acute hepatic porphyrias (AHP), an inherited family of liver disorders caused by an enzyme deficiency characterized by abdominal pain and … read more...

Alnylam competes enrollment in late-stage study of givosiran in AHP

via: SeekingAlpha at 2018-08-21 07:29:04:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) has completed enrollment of 94 subjects in its Phase 3 ENVISION study evaluating givosiran in patients with acute hepatic porphyrias (AHP), an inherited family of liver disorders caused by an enzyme deficiency characterized by abdominal pain and … read more...

Alnylam competes enrollment in late-stage study of givosiran in AHP

via: SeekingAlpha at 2018-08-21 07:29:04:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) has completed enrollment of 94 subjects in its Phase 3 ENVISION study evaluating givosiran in patients with acute hepatic porphyrias (AHP), an inherited family of liver disorders caused by an enzyme deficiency characterized by abdominal pain and … read more...

Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)

via: Business Wire at 2018-08-21 07:00:00:000

Enrollment Completed Ahead of Schedule, Eight Months After First Patient Randomized Company Remains on Track to Report Interim Analysis Data by the End of September and Full Study Data in Early 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq:… read more...

Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)

via: Business Wire at 2018-08-21 07:00:00:000

Enrollment Completed Ahead of Schedule, Eight Months After First Patient Randomized Company Remains on Track to Report Interim Analysis Data by the End of September and Full Study Data in Early 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq:… read more...

Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)

via: Business Wire at 2018-08-21 07:00:00:000

Enrollment Completed Ahead of Schedule, Eight Months After First Patient Randomized Company Remains on Track to Report Interim Analysis Data by the End of September and Full Study Data in Early 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq:… read more...

The Battle For Best-In-Class In ATTR Has Begun

via: SeekingAlpha at 2018-08-16 11:52:57:000

With Alnylam (NASDAQ: ALNY ) securing FDA approval for Onpattro on Friday, August 10 th , 2018, the battle for "best-in-class" in transthyretin amyloidosis (ATTR) has officially begun. This approval gives Alnylam the early lead. Other competitors in the clinic include Ionis (NASDAQ:… read more...

The Battle For Best-In-Class In ATTR Has Begun

via: SeekingAlpha at 2018-08-16 11:52:57:000

With Alnylam (NASDAQ: ALNY ) securing FDA approval for Onpattro on Friday, August 10 th , 2018, the battle for "best-in-class" in transthyretin amyloidosis (ATTR) has officially begun. This approval gives Alnylam the early lead. Other competitors in the clinic include Ionis (NASDAQ:… read more...

The Battle For Best-In-Class In ATTR Has Begun

via: SeekingAlpha at 2018-08-16 11:52:57:000

With Alnylam (NASDAQ: ALNY ) securing FDA approval for Onpattro on Friday, August 10 th , 2018, the battle for "best-in-class" in transthyretin amyloidosis (ATTR) has officially begun. This approval gives Alnylam the early lead. Other competitors in the clinic include Ionis (NASDAQ:… read more...

Alnylam Pharmaceuticals (ALNY) Lumasarin Trial Data - Slideshow

via: SeekingAlpha at 2018-08-15 14:52:37:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review

via: SeekingAlpha at 2018-08-14 08:58:04:000

Stocks in News: RDHL, REGN RedHill Bio nabs U.S. patent covering RHB-104 and RHB-204 Discussion : RedHill Biopharma ( RDHL ) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The … read more...

Alnylam Pharmaceutical's (ALNY) Conference Call to Discuss FDA Approval of ONPATTRO (Patisiran) - Slideshow

via: SeekingAlpha at 2018-08-13 13:39:48:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Premarket Losers as of 9:05 am (8/13/2018)

via: SeekingAlpha at 2018-08-13 09:16:29:000

DY -21% on cutting quarterly and full-year guidance. More news on: Dycom Industries Inc., Bright Scholar Education, RYB Education, Stocks on the move, , Read more … read more...

3 Things In Biotech, August 13: Rare Disease Approvals And Other Forward Momentum

via: SeekingAlpha at 2018-08-13 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Alnylam clears the finish in amyloidosis Company: Alnylam Pharmaceuticals ( ALNY ) Therapy: Patisiran Disease:… read more...

Alnylam Receives First Ever FDA Approval For RNAi Therapeutic Treating Rare Disease Making History

via: SeekingAlpha at 2018-08-13 02:14:28:000

Recently, Alnylam Pharmaceuticals ( ALNY ) announced that it had received FDA approval for its drug Patisiran . This is the first of many approvals, because the EMA is also reviewing the drug for treating the same disease hereditary ATTR ((hATTR)) amyloidosis. The company has a pipeline f… read more...

Alnylam Announces Alignment on Value-Based Agreements with Leading Health Insurers and Launches Comprehensive Patient Support Services for ONPATTRO(TM) (patisiran)

via: Business Wire at 2018-08-10 14:37:00:000

Structure of Value-Based Arrangements Agreed in Principle with Harvard Pilgrim Health Care and Other Major Health Insurers Alnylam Assist Program Designed to Facilitate Access to ONPATTRO and Provide Dedicated Patient Support Alnylam P… read more...

Alnylam Announces Alignment on Value-Based Agreements with Leading Health Insurers and Launches Comprehensive Patient Support Services for ONPATTRO(TM) (patisiran)

via: Business Wire at 2018-08-10 14:37:00:000

Structure of Value-Based Arrangements Agreed in Principle with Harvard Pilgrim Health Care and Other Major Health Insurers Alnylam Assist Program Designed to Facilitate Access to ONPATTRO and Provide Dedicated Patient Support Alnylam P… read more...

Alnylam Announces Alignment on Value-Based Agreements with Leading Health Insurers and Launches Comprehensive Patient Support Services for ONPATTRO(TM) (patisiran)

via: Business Wire at 2018-08-10 14:37:00:000

Structure of Value-Based Arrangements Agreed in Principle with Harvard Pilgrim Health Care and Other Major Health Insurers Alnylam Assist Program Designed to Facilitate Access to ONPATTRO and Provide Dedicated Patient Support Alnylam P… read more...

Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO(TM) (patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

via: Business Wire at 2018-08-10 14:28:00:000

First and Only FDA-approved Treatment Available in the United States for this Indication ONPATTRO Shown to Improve Polyneuropathy Relative to Placebo, with Reversal of Neuropathy Impairment Compared to Baseline in Majority of Patients I… read more...

Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO(TM) (patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

via: Business Wire at 2018-08-10 14:28:00:000

First and Only FDA-approved Treatment Available in the United States for this Indication ONPATTRO Shown to Improve Polyneuropathy Relative to Placebo, with Reversal of Neuropathy Impairment Compared to Baseline in Majority of Patients I… read more...

Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO(TM) (patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

via: Business Wire at 2018-08-10 14:28:00:000

First and Only FDA-approved Treatment Available in the United States for this Indication ONPATTRO Shown to Improve Polyneuropathy Relative to Placebo, with Reversal of Neuropathy Impairment Compared to Baseline in Majority of Patients I… read more...

Alnylam shares halted pending news

via: SeekingAlpha at 2018-08-10 12:27:54:000

Nasdaq has suspended trading in Alnylam Pharmaceuticals ( ALNY +3.5% ) pending the release of news, most likely related to an FDA nod for patisiran for hATTR. The agency's action date is Saturday (meaning today). More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., H… read more...

Alnylam shares halted pending news

via: SeekingAlpha at 2018-08-10 12:27:54:000

Nasdaq has suspended trading in Alnylam Pharmaceuticals ( ALNY +3.5% ) pending the release of news, most likely related to an FDA nod for patisiran for hATTR. The agency's action date is Saturday (meaning today). More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., H… read more...

Alnylam shares halted pending news

via: SeekingAlpha at 2018-08-10 12:27:54:000

Nasdaq has suspended trading in Alnylam Pharmaceuticals ( ALNY +3.5% ) pending the release of news, most likely related to an FDA nod for patisiran for hATTR. The agency's action date is Saturday (meaning today). More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., H… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Alnylam About A Week Away From Its First Approval

via: SeekingAlpha at 2018-08-06 08:02:36:000

With an FDA PDUFA date about one week away for its lead drug patisiran (which Alnylam ( ALNY ) will market as Onpattro), the value in the companys second quarter earnings report was mostly in regard to its pipeline updates. Alynylam has ample cash to continue moving i… read more...

Your Daily Pharma Scoop: Insmed's AdCom, Opko Progresses, Roche PRIMEd

via: SeekingAlpha at 2018-08-06 01:39:48:000

Stocks in News: INSM, OPK Insmed up 7% premarket ahead of Ad Com review of inhalable amikacin for NTM lung disease Discussion : Insmed ( INSM ) released briefing documents before upcoming Ad Com on Aug 7. The Ad Com will review the companys marketing application for amikacin l… read more...

Key events next week for healthcare investors

via: SeekingAlpha at 2018-08-03 07:58:17:000

Noteworthy events during the week of August 5-11 for healthcare investors. More news on: Insmed, Inc., Pain Therapeutics, Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...

Key events next week for healthcare investors

via: SeekingAlpha at 2018-08-03 07:58:17:000

Noteworthy events during the week of August 5-11 for healthcare investors. More news on: Insmed, Inc., Pain Therapeutics, Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...

Key events next week for healthcare investors

via: SeekingAlpha at 2018-08-03 07:58:17:000

Noteworthy events during the week of August 5-11 for healthcare investors. More news on: Insmed, Inc., Pain Therapeutics, Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...

Alnylam Announces that the United Kingdom's MHRA Grants Early Access to Patisiran

via: Business Wire at 2018-08-03 07:00:00:000

Positive Scientific Opinion Under Early Access to Medicines Scheme will Make Patisiran Treatment Available for UK hATTR Amyloidosis Patients Before Marketing Authorization Patisiran Indicated Within EAMS for the Treatment of Adults with hATTR Amyloidosis &#x2… read more...

Alnylam Announces that the United Kingdom's MHRA Grants Early Access to Patisiran

via: Business Wire at 2018-08-03 07:00:00:000

Positive Scientific Opinion Under Early Access to Medicines Scheme will Make Patisiran Treatment Available for UK hATTR Amyloidosis Patients Before Marketing Authorization Patisiran Indicated Within EAMS for the Treatment of Adults with hATTR Amyloidosis &#x2… read more...

Alnylam Announces that the United Kingdom's MHRA Grants Early Access to Patisiran

via: Business Wire at 2018-08-03 07:00:00:000

Positive Scientific Opinion Under Early Access to Medicines Scheme will Make Patisiran Treatment Available for UK hATTR Amyloidosis Patients Before Marketing Authorization Patisiran Indicated Within EAMS for the Treatment of Adults with hATTR Amyloidosis &#x2… read more...

Alnylam Pharmaceuticals (ALNY) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-02 19:16:17:000

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2018 Earnings Call August 02, 2018 8:30 am ET Executives Christine Regan Lindenboom - Alnylam Pharmaceuticals, Inc. John M. Maraganore - Alnylam Pharmaceuticals, Inc. Yvonne L. Greenstreet - Alnylam Pharmaceuticals, Inc. Manmeet Singh Son… read more...

Alnylam Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-08-02 10:26:44:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Alnylam Pharmaceuticals Q2 revenues up 88%

via: SeekingAlpha at 2018-08-02 09:34:19:000

Alnylam Pharmaceuticals ( ALNY +3.2% ) Q2 results : Revenues: $29.9M (+88.1%). More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Alnylam Pharmaceuticals beats by $0.16, beats on revenue

via: SeekingAlpha at 2018-08-02 08:02:08:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q2 EPS of -$1.61 beats by $0.16 . More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity

via: Business Wire at 2018-08-02 08:00:00:000

Received Positive CHMP Opinion for ONPATTRO in Europe for the Treatment of hATTR Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy and On Track for August 11 PDUFA Date in U.S. Achieved Robust Enrollment in ENVISION Phase 3 Study of… read more...

Notable earnings before Thursday's open

via: SeekingAlpha at 2018-08-01 17:30:46:000

AAON , AAWW , ABC , ACIW , ACOR , AET , AGIO , ALE , ALNY , AMAG , AMCX , APO , APRN , ARES , AROC , ARW , AVP , BCE , BDX , BLL , BSIG , CBM , CBRE , CBZ , CCOI , CDW , CEIX , CHD , CI , CJ , CLX , CNQ , CNSL , CNX , CNXM , COT , CRS , CTSH , DNOW , … read more...

Your Daily Pharma Scoop: Tonix Halted, Endo Begins Shipment, Insys FDA-Rejected

via: SeekingAlpha at 2018-07-30 15:55:08:000

Stocks in News: ENDP, TNXP Tonix Pharma PTSD study fails; shares halted Discussion : The Phase 3 study of Tonix Pharmas ( TNXP ) Tonmya (previously TNX-102) in military-related PTSD will be halted. The decision is taken because, at week 12, the primary endpoint of separation f… read more...

Your Daily Pharma Scoop: Tonix Halted, Endo Begins Shipment, Insys FDA-Rejected

via: SeekingAlpha at 2018-07-30 15:55:08:000

Stocks in News: ENDP, TNXP Tonix Pharma PTSD study fails; shares halted Discussion : The Phase 3 study of Tonix Pharmas ( TNXP ) Tonmya (previously TNX-102) in military-related PTSD will be halted. The decision is taken because, at week 12, the primary endpoint of separation f… read more...

3 Things In Biotech, July 30: Europe News Continues To Dominate

via: SeekingAlpha at 2018-07-30 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Janssen headlines myeloma therapy in Europe Company: Johnson & Johnson ( JNJ ) and G… read more...

3 Things In Biotech, July 30: Europe News Continues To Dominate

via: SeekingAlpha at 2018-07-30 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Janssen headlines myeloma therapy in Europe Company: Johnson & Johnson ( JNJ ) and G… read more...

Alnylam to Webcast Conference Call Discussing Second Quarter 2018 Financial Results

via: Business Wire at 2018-07-27 09:27:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2018 on Thursday, August 2, 2018, before the U.S. financial markets open. Management will provide an update … read more...

Alnylam to Webcast Conference Call Discussing Second Quarter 2018 Financial Results

via: Business Wire at 2018-07-27 09:27:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2018 on Thursday, August 2, 2018, before the U.S. financial markets open. Management will provide an update … read more...

Alnylam to Webcast Conference Call Discussing Second Quarter 2018 Financial Results

via: Business Wire at 2018-07-27 09:27:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2018 on Thursday, August 2, 2018, before the U.S. financial markets open. Management will provide an update … read more...

Alnylam Receives Positive CHMP Opinion for ONPATTRO(TM) (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy

via: Business Wire at 2018-07-27 07:15:00:000

European Commission Decision Expected in September Recommended Summary of Product Characteristics (SmPC) Includes Data on Secondary and Exploratory Endpoints, Including Results on Cardiac Parameters Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY… read more...

Alnylam Receives Positive CHMP Opinion for ONPATTRO(TM) (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy

via: Business Wire at 2018-07-27 07:15:00:000

European Commission Decision Expected in September Recommended Summary of Product Characteristics (SmPC) Includes Data on Secondary and Exploratory Endpoints, Including Results on Cardiac Parameters Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY… read more...

Alnylam Receives Positive CHMP Opinion for ONPATTRO(TM) (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy

via: Business Wire at 2018-07-27 07:15:00:000

European Commission Decision Expected in September Recommended Summary of Product Characteristics (SmPC) Includes Data on Secondary and Exploratory Endpoints, Including Results on Cardiac Parameters Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY… read more...

Alnylam Pharmaceuticals (ALNY) Updates On Givosiran, in Development for the Treatment of Acute Hepatic Porphyrias (RNAi Roundtable) - Slideshow

via: SeekingAlpha at 2018-07-24 13:42:52:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Alnylam Pharmaceuticals (ALNY) Updates On Givosiran, in Development for the Treatment of Acute Hepatic Porphyrias (RNAi Roundtable) - Slideshow

via: SeekingAlpha at 2018-07-24 13:42:52:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Alnylam Pharmaceuticals (ALNY) Updates On Givosiran, in Development for the Treatment of Acute Hepatic Porphyrias (RNAi Roundtable) - Slideshow

via: SeekingAlpha at 2018-07-24 13:42:52:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Alnylam Presents New Analyses of Clinical Results from APOLLO Phase 3 Study of Patisiran at 2018 Peripheral Nerve Society Annual Meeting

via: Business Wire at 2018-07-23 07:00:00:000

Patisiran-Treated Patients Showed Improvements in Overall Health Status Compared to Placebo Indirect Analysis Shows Patisirans Impact on Measures of Neuropathy and Quality of Life in APOLLO Study Relative to those Measured in Randomized Study of Tafam… read more...

Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun

via: SeekingAlpha at 2018-07-18 16:03:11:000

While enthusiasm may be necessary for great accomplishments elsewhere, on Wall Street it almost invariably leads to disaster. -Benjamin Graham, The Intelligent Investor It's no wonder The Street has witnessed a 200% run-up over the past year for Arbutus Biopharma ( ABUS ). The Canadi… read more...

Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun

via: SeekingAlpha at 2018-07-18 16:03:11:000

While enthusiasm may be necessary for great accomplishments elsewhere, on Wall Street it almost invariably leads to disaster. -Benjamin Graham, The Intelligent Investor It's no wonder The Street has witnessed a 200% run-up over the past year for Arbutus Biopharma ( ABUS ). The Canadi… read more...

Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun

via: SeekingAlpha at 2018-07-18 16:03:11:000

While enthusiasm may be necessary for great accomplishments elsewhere, on Wall Street it almost invariably leads to disaster. -Benjamin Graham, The Intelligent Investor It's no wonder The Street has witnessed a 200% run-up over the past year for Arbutus Biopharma ( ABUS ). The Canadi… read more...

Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine

via: Business Wire at 2018-07-04 17:10:00:000

In Patients with Hereditary ATTR Amyloidosis, Patisiran Treatment Improved Polyneuropathy and Quality of Life Relative to Placebo Majority of Patients Receiving Patisiran Experienced Improvement in Polyneuropathy and Quality of Life Relative to Baseline &#x22… read more...

Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine

via: Business Wire at 2018-07-04 17:10:00:000

In Patients with Hereditary ATTR Amyloidosis, Patisiran Treatment Improved Polyneuropathy and Quality of Life Relative to Placebo Majority of Patients Receiving Patisiran Experienced Improvement in Polyneuropathy and Quality of Life Relative to Baseline &#x22… read more...

Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine

via: Business Wire at 2018-07-04 17:10:00:000

In Patients with Hereditary ATTR Amyloidosis, Patisiran Treatment Improved Polyneuropathy and Quality of Life Relative to Placebo Majority of Patients Receiving Patisiran Experienced Improvement in Polyneuropathy and Quality of Life Relative to Baseline &#x22… read more...

Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation

via: SeekingAlpha at 2018-06-29 02:52:13:000

A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...

Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation

via: SeekingAlpha at 2018-06-29 02:52:13:000

A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...

Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation

via: SeekingAlpha at 2018-06-29 02:52:13:000

A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...

Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation

via: SeekingAlpha at 2018-06-29 02:52:13:000

A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...

Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation

via: SeekingAlpha at 2018-06-29 02:52:13:000

A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...

Alnylam Pharmaceuticals (ALNY) Platform Advances In RNAi Therapeutics - Slideshow

via: SeekingAlpha at 2018-06-26 13:55:03:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Alnylam Pharmaceuticals (ALNY) Platform Advances In RNAi Therapeutics - Slideshow

via: SeekingAlpha at 2018-06-26 13:55:03:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Alnylam Pharmaceuticals (ALNY) Platform Advances In RNAi Therapeutics - Slideshow

via: SeekingAlpha at 2018-06-26 13:55:03:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Alnylam to Host Fifth Annual "RNAi Roundtable" Webcast Series

via: Business Wire at 2018-06-21 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 5 th annual series of RNAi Roundtable webcasts this summer. The 2018 series will offer a range of presentations from Alnylam scientists, clin… read more...

Alnylam to Host Fifth Annual "RNAi Roundtable" Webcast Series

via: Business Wire at 2018-06-21 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 5 th annual series of RNAi Roundtable webcasts this summer. The 2018 series will offer a range of presentations from Alnylam scientists, clin… read more...

Alnylam Expands Senior Leadership Team with Two Key Appointments

via: Business Wire at 2018-06-20 07:00:00:000

Company Appoints Senior Vice President, Head of Asia and Senior Vice President, Head of Medical Affairs Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointments of two accomplished biotech executives… read more...

Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology

via: Business Wire at 2018-06-15 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, will be presented at t… read more...

Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology

via: Business Wire at 2018-06-15 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, will be presented at t… read more...

Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology

via: Business Wire at 2018-06-15 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, will be presented at t… read more...

Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology

via: Business Wire at 2018-06-15 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, will be presented at t… read more...

Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology

via: Business Wire at 2018-06-15 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, will be presented at t… read more...

Biotech industry group criticized for party featuring topless dancers

via: SeekingAlpha at 2018-06-13 12:05:05:000

Certain biotechs are scrambling to distance themselves from the uproar over a party at the 2018 BIO International Convention in Boston last week. Remarkably tone-deaf to the MeToo movement, the party featured topless dancers with company logos painted on their bodies. More news on: Bayer… read more...

Biotech industry group criticized for party featuring topless dancers

via: SeekingAlpha at 2018-06-13 12:05:05:000

Certain biotechs are scrambling to distance themselves from the uproar over a party at the 2018 BIO International Convention in Boston last week. Remarkably tone-deaf to the MeToo movement, the party featured topless dancers with company logos painted on their bodies. More news on: Bayer… read more...

Nash players perk up on Galmed surge

via: SeekingAlpha at 2018-06-12 11:25:16:000

Money flow has perked up in certain NASH players after Galmed Pharmaceuticals ( GLMD +183.4% ) reported positive results on Aramchol this morning. More news on: Galmed Pharmaceuticals Ltd., CymaBay Therapeutics, Intercept Pharmaceuticals, Healthcare stocks news, Stocks on the move, R… read more...

Over 700 Alnylam Employees Volunteer at the Company's 4th Annual "Helping Hands" Community Service Day

via: Business Wire at 2018-06-12 08:00:00:000

Alnylam Supports 23 Local Organizations in theGreater Boston Area and Western Europe Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today kicked off its fourth annual company-wide Helping Hands Communi… read more...

Alnylam Pharmaceuticals Continues To Develop Options Outside Of Amyloidosis

via: SeekingAlpha at 2018-06-12 07:48:32:000

With a $10 billion market cap, its hard to call Alnylam ( ALNY ) overlooked, but I do believe the shares of this maturing biotech are undervalued as the company approaches a window that should see multiple new product approvals through 2020. Most recently, Alnylam has offered up some… read more...

Your Daily Pharma Scoop: Zealand Dips, Eloxx Surges, Venetoclax Approved

via: SeekingAlpha at 2018-06-11 08:00:00:000

Analysis Focus: ZEAL Zealand Pharma ( ZEAL ) is a small Danish company that specializes in gastroenteric and metabolic diseases. The company has late-stage clinical programs with glepaglutide and three dasiglucagon product candidates. They also have a late-stage program in Phase 3 developm… read more...

3 Things In Biotech, June 9: AbbVie Rules The CLL Roost

via: SeekingAlpha at 2018-06-10 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

Eidos Therapeutics Readies $100 Million U.S. IPO

via: SeekingAlpha at 2018-06-08 12:01:02:000

Quick Take Eidos Therapeutics ( EIDX ) intends to sell shares of its common stock for gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement. The firm is a subsidiary of BridgeBio Pharma with the mission to improve and prolong the lives of patients s… read more...

Eidos Therapeutics Readies $100 Million U.S. IPO

via: SeekingAlpha at 2018-06-08 12:01:02:000

Quick Take Eidos Therapeutics ( EIDX ) intends to sell shares of its common stock for gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement. The firm is a subsidiary of BridgeBio Pharma with the mission to improve and prolong the lives of patients s… read more...

Alnylam's lumasiran shows positive effect in Phase 1/2 PH1 study

via: SeekingAlpha at 2018-06-08 07:20:19:000

Updated results from a Phase 1/2 clinical trial assessing Alnylam Pharmaceuticals' (NASDAQ: ALNY ) lumasiran in patients with primary hyperoxaluria type 1 (PH1) continued to show a treatment effect. The data were presented at OxalEurope in Naples, Italy. More news on: Alnylam Pharmaceut… read more...

Alnylam's lumasiran shows positive effect in Phase 1/2 PH1 study

via: SeekingAlpha at 2018-06-08 07:20:19:000

Updated results from a Phase 1/2 clinical trial assessing Alnylam Pharmaceuticals' (NASDAQ: ALNY ) lumasiran in patients with primary hyperoxaluria type 1 (PH1) continued to show a treatment effect. The data were presented at OxalEurope in Naples, Italy. More news on: Alnylam Pharmaceut… read more...

Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)

via: Business Wire at 2018-06-08 07:00:00:000

Patients Receiving Investigational Lumasiran Experienced Substantial and Sustained Reductions in Urinary Oxalate, Confirming Potential for RNAi-Mediated Inhibition of Glycolate Oxidase as a Robust Therapeutic Approach for PH1 Lumasiran Generally Well Tolerate… read more...

Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)

via: Business Wire at 2018-06-08 07:00:00:000

Patients Receiving Investigational Lumasiran Experienced Substantial and Sustained Reductions in Urinary Oxalate, Confirming Potential for RNAi-Mediated Inhibition of Glycolate Oxidase as a Robust Therapeutic Approach for PH1 Lumasiran Generally Well Tolerate… read more...

Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells

via: SeekingAlpha at 2018-06-08 03:06:02:000

The best way to measure your investing success is not by whether you're beating the market but by whether you've put in place a financial plan and a behavioral discipline that are likely to get you where you want to go. - Benjamin Graham We have presented many stellar therapeutic… read more...

Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells

via: SeekingAlpha at 2018-06-08 03:06:02:000

The best way to measure your investing success is not by whether you're beating the market but by whether you've put in place a financial plan and a behavioral discipline that are likely to get you where you want to go. - Benjamin Graham We have presented many stellar therapeutic… read more...

Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up

via: SeekingAlpha at 2018-06-06 01:36:03:000

Analysis Focus:IOVA Iovance Biotherapeutics (IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2… read more...

Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up

via: SeekingAlpha at 2018-06-06 01:36:03:000

Analysis Focus:IOVA Iovance Biotherapeutics (IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2… read more...

Alnylam receives ODD for ALN-TTRsc02 in U.S. for the treatment of transthyretin-mediated amyloidosis

via: SeekingAlpha at 2018-06-04 08:07:54:000

The FDA grants Orphan Drug Designation to Alnylam Pharmaceuticals' (NASDAQ: ALNY ), ALN-TTRsc02, an investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Alnylam receives ODD for ALN-TTRsc02 in U.S. for the treatment of transthyretin-mediated amyloidosis

via: SeekingAlpha at 2018-06-04 08:07:54:000

The FDA grants Orphan Drug Designation to Alnylam Pharmaceuticals' (NASDAQ: ALNY ), ALN-TTRsc02, an investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis

via: Business Wire at 2018-06-04 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALN-TTRsc02, an investigational RNAi therapeutic for the treatment of transthyretin-mediated… read more...

Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis

via: Business Wire at 2018-06-04 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALN-TTRsc02, an investigational RNAi therapeutic for the treatment of transthyretin-mediated… read more...

Thoughts On Joel Greenblatt At Google

via: SeekingAlpha at 2018-06-04 05:58:56:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) When An Investment Method Stops Working Each week for the past year, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an " investing … read more...

Thoughts On Joel Greenblatt At Google

via: SeekingAlpha at 2018-06-04 05:58:56:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) When An Investment Method Stops Working Each week for the past year, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an " investing … read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Bulletproof Investing Performance Update: Week 27

via: SeekingAlpha at 2018-06-01 02:42:50:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...

Alnylam to Webcast Presentations at Upcoming June Investor Conferences

via: Business Wire at 2018-05-29 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Bernstein 34 th Annual Strategic Decisions Conference on Friday, June 1, 2018 at 9:00 am ET at the Grand … read more...

Alnylam to Webcast Presentations at Upcoming June Investor Conferences

via: Business Wire at 2018-05-29 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Bernstein 34 th Annual Strategic Decisions Conference on Friday, June 1, 2018 at 9:00 am ET at the Grand … read more...

Alnylam to Webcast Presentations at Upcoming June Investor Conferences

via: Business Wire at 2018-05-29 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Bernstein 34 th Annual Strategic Decisions Conference on Friday, June 1, 2018 at 9:00 am ET at the Grand … read more...

Eidos Therapeutics files for initial public offering

via: SeekingAlpha at 2018-05-25 17:13:24:000

Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...

Eidos Therapeutics files for initial public offering

via: SeekingAlpha at 2018-05-25 17:13:24:000

Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...

Eidos Therapeutics files for initial public offering

via: SeekingAlpha at 2018-05-25 17:13:24:000

Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...

Eidos Therapeutics files for initial public offering

via: SeekingAlpha at 2018-05-25 17:13:24:000

Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...

Eidos Therapeutics files for initial public offering

via: SeekingAlpha at 2018-05-25 17:13:24:000

Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...

Eidos Therapeutics files for initial public offering

via: SeekingAlpha at 2018-05-25 17:13:24:000

Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...

3 Things In Biotech, May 24: Immunotherapy Makes Yet Another Foray

via: SeekingAlpha at 2018-05-25 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 24: Immunotherapy Makes Yet Another Foray

via: SeekingAlpha at 2018-05-25 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 24: Immunotherapy Makes Yet Another Foray

via: SeekingAlpha at 2018-05-25 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 24: Immunotherapy Makes Yet Another Foray

via: SeekingAlpha at 2018-05-25 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 24: Immunotherapy Makes Yet Another Foray

via: SeekingAlpha at 2018-05-25 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 24: Immunotherapy Makes Yet Another Foray

via: SeekingAlpha at 2018-05-25 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Alnylam Appoints Colleen Reitan to the Board of Directors

via: Business Wire at 2018-05-15 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylams Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of… read more...

Alnylam Appoints Colleen Reitan to the Board of Directors

via: Business Wire at 2018-05-15 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylams Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of… read more...

Alnylam Appoints Colleen Reitan to the Board of Directors

via: Business Wire at 2018-05-15 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylams Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of… read more...

Alnylam Appoints Colleen Reitan to the Board of Directors

via: Business Wire at 2018-05-15 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylams Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of… read more...

Alnylam Appoints Colleen Reitan to the Board of Directors

via: Business Wire at 2018-05-15 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylams Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of… read more...

Alnylam Appoints Colleen Reitan to the Board of Directors

via: Business Wire at 2018-05-15 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylams Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of… read more...

Biotech Analysis Central Pharma News: Takeda's Acquisition Win, Ionis And Akcea Tumble, Alnylam's Advance In CNS

via: SeekingAlpha at 2018-05-09 01:40:03:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Takeda Acquires Shire For $62 Billion News: It was announced recently that Takeda ( TKPYY ) would pay $62 billion in total to acquire rare disea… read more...

Biotech Analysis Central Pharma News: Takeda's Acquisition Win, Ionis And Akcea Tumble, Alnylam's Advance In CNS

via: SeekingAlpha at 2018-05-09 01:40:03:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Takeda Acquires Shire For $62 Billion News: It was announced recently that Takeda ( TKPYY ) would pay $62 billion in total to acquire rare disea… read more...

Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics

via: Business Wire at 2018-05-08 07:00:00:000

Novel siRNA Conjugates Achieve Robust, Durable, and Broadly Distributed Silencing of CNS Gene Transcripts Following a Single Intrathecal Injection Company Expects First CNS-Targeted Development Candidate in 2018, First IND in Late 2019/Early 2020, and Capacit… read more...

Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics

via: Business Wire at 2018-05-08 07:00:00:000

Novel siRNA Conjugates Achieve Robust, Durable, and Broadly Distributed Silencing of CNS Gene Transcripts Following a Single Intrathecal Injection Company Expects First CNS-Targeted Development Candidate in 2018, First IND in Late 2019/Early 2020, and Capacit… read more...

Alnylam Gets A Shortcut For Lumasiran... This News Is Highly Welcome

via: SeekingAlpha at 2018-05-08 00:53:33:000

It was recently announced that Alnylam Pharmaceuticals ( ALNY ) was able to obtain a quicker path to approval for lumasiran. This will put the biotech ahead of schedule with approval of another one of its drugs in the pipeline possibly by 2020. That's because it is expecting a decision from … read more...

Alnylam Gets A Shortcut For Lumasiran... This News Is Highly Welcome

via: SeekingAlpha at 2018-05-08 00:53:33:000

It was recently announced that Alnylam Pharmaceuticals ( ALNY ) was able to obtain a quicker path to approval for lumasiran. This will put the biotech ahead of schedule with approval of another one of its drugs in the pipeline possibly by 2020. That's because it is expecting a decision from … read more...

Despite Recurrent Market Jitters, Alnylam Is Closing In On Multiple Drug Approvals

via: SeekingAlpha at 2018-05-07 08:00:12:000

Holding shares in Alnylam Pharmaceuticals ( ALNY ) isnt for the weak-hearted, as seen recently in reaction to a competitors unexpectedly strong clinical data. While Alnylam has long been volatile, and remains risky given the nature of the diseases it targets and its reliance … read more...

Despite Recurrent Market Jitters, Alnylam Is Closing In On Multiple Drug Approvals

via: SeekingAlpha at 2018-05-07 08:00:12:000

Holding shares in Alnylam Pharmaceuticals ( ALNY ) isnt for the weak-hearted, as seen recently in reaction to a competitors unexpectedly strong clinical data. While Alnylam has long been volatile, and remains risky given the nature of the diseases it targets and its reliance … read more...

Your Daily Pharma Scoop: Alnylam Update, Malinckrodt's Adcom Failure, Anika's Drug Recall

via: SeekingAlpha at 2018-05-07 08:00:00:000

Analysis focus: ALNY Alnylam (ALNY), a leading RNAi therapeutics company, reported earnings last week. It beat on EPS, which at -$1.22 beat by $0.25. However, its revenue , despite rising 15% y/y, stood at $21.9mn, $8.25mn short of consensus. So, the company must have managed to cut costs… read more...

Your Daily Pharma Scoop: Alnylam Update, Malinckrodt's Adcom Failure, Anika's Drug Recall

via: SeekingAlpha at 2018-05-07 08:00:00:000

Analysis focus: ALNY Alnylam (ALNY), a leading RNAi therapeutics company, reported earnings last week. It beat on EPS, which at -$1.22 beat by $0.25. However, its revenue , despite rising 15% y/y, stood at $21.9mn, $8.25mn short of consensus. So, the company must have managed to cut costs… read more...

3 Things In Biotech, May 4: Merck's New Combo, Alnylam Jump Starts, Ocata Gone Forever?

via: SeekingAlpha at 2018-05-05 08:54:11:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 4: Merck's New Combo, Alnylam Jump Starts, Ocata Gone Forever?

via: SeekingAlpha at 2018-05-05 08:54:11:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

FDA extends action date for Akcea's inotersen to October 6; shares down 6% premarket

via: SeekingAlpha at 2018-05-04 09:25:07:000

Akcea Therapeutics (NASDAQ: AKCA ) announces that the FDA has established a new action date of October 6 for the review of its marketing application seeking approval for inotersen, branded as TEGSEDI, for the treatment of hereditary transthyretin amyloidosis (hATTR). The agency extended it… read more...

FDA extends action date for Akcea's inotersen to October 6; shares down 6% premarket

via: SeekingAlpha at 2018-05-04 09:25:07:000

Akcea Therapeutics (NASDAQ: AKCA ) announces that the FDA has established a new action date of October 6 for the review of its marketing application seeking approval for inotersen, branded as TEGSEDI, for the treatment of hereditary transthyretin amyloidosis (hATTR). The agency extended it… read more...

Alnylam Pharmaceuticals (ALNY) Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-04 00:55:05:000

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2018 Earnings Call May 03, 2018 4:30 pm ET Executives Christine Regan Lindenboom - Alnylam Pharmaceuticals, Inc. John M. Maraganore - Alnylam Pharmaceuticals, Inc. Akshay K. Vaishnaw - Alnylam Pharmaceuticals, Inc. Manmeet Singh Soni - Al… read more...

Alnylam Pharmaceuticals (ALNY) Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-04 00:55:05:000

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2018 Earnings Call May 03, 2018 4:30 pm ET Executives Christine Regan Lindenboom - Alnylam Pharmaceuticals, Inc. John M. Maraganore - Alnylam Pharmaceuticals, Inc. Akshay K. Vaishnaw - Alnylam Pharmaceuticals, Inc. Manmeet Singh Soni - Al… read more...

Alnylam Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-03 22:49:20:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2018 Q1 earnings Read more … read more...

Alnylam Pharmaceuticals (ALNY) Presents At BIO CEO & Investor Conference - Slideshow

via: SeekingAlpha at 2018-02-13 13:56:52:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Biotech Forum Daily Digest For February 12th

via: SeekingAlpha at 2018-02-12 10:14:39:000

T here are some days we can claim and there are other days that claim us . Kamand Kojouri Investors got treated like 'rented mules' this week as the markets suffered their worst weekly loss in some two years. Four of the five trading sessions featured over 1,000 point sw… read more...

Biotech Forum Daily Digest For February 12th

via: SeekingAlpha at 2018-02-12 10:14:39:000

T here are some days we can claim and there are other days that claim us . Kamand Kojouri Investors got treated like 'rented mules' this week as the markets suffered their worst weekly loss in some two years. Four of the five trading sessions featured over 1,000 point sw… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-02-09 12:34:12:000

Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-02-09 12:34:12:000

Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-02-09 12:34:12:000

Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-02-09 12:34:12:000

Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-02-09 12:34:12:000

Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-08 20:12:04:000

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2017 Earnings Conference Call February 08, 2018 4:30 PM ET Executives Christine Lindenboom Vice President-Investor Relations and Corporate Communications John Maraganore Chief Executive Officer Akshay Vaishnaw Exe… read more...

Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-08 20:12:04:000

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2017 Earnings Conference Call February 08, 2018 4:30 PM ET Executives Christine Lindenboom Vice President-Investor Relations and Corporate Communications John Maraganore Chief Executive Officer Akshay Vaishnaw Exe… read more...

Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-08 20:12:04:000

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2017 Earnings Conference Call February 08, 2018 4:30 PM ET Executives Christine Lindenboom Vice President-Investor Relations and Corporate Communications John Maraganore Chief Executive Officer Akshay Vaishnaw Exe… read more...

Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-08 20:12:04:000

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2017 Earnings Conference Call February 08, 2018 4:30 PM ET Executives Christine Lindenboom Vice President-Investor Relations and Corporate Communications John Maraganore Chief Executive Officer Akshay Vaishnaw Exe… read more...

Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-08 20:12:04:000

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2017 Earnings Conference Call February 08, 2018 4:30 PM ET Executives Christine Lindenboom Vice President-Investor Relations and Corporate Communications John Maraganore Chief Executive Officer Akshay Vaishnaw Exe… read more...

Alnylam Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-08 13:30:18:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Alnylam Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-08 13:30:18:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Alnylam Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-08 13:30:18:000

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Alnylam Pharmaceuticals beats by $0.19, beats on revenue

via: SeekingAlpha at 2018-02-08 08:01:32:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q4 EPS of -$1.20 beats by $0.19 . Revenue of $37.9M (+117.2% Y/Y) beats by $16.1M . Press Release More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Alnylam Pharmaceuticals beats by $0.19, beats on revenue

via: SeekingAlpha at 2018-02-08 08:01:32:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q4 EPS of -$1.20 beats by $0.19 . Revenue of $37.9M (+117.2% Y/Y) beats by $16.1M . Press Release More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Alnylam Pharmaceuticals beats by $0.19, beats on revenue

via: SeekingAlpha at 2018-02-08 08:01:32:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q4 EPS of -$1.20 beats by $0.19 . Revenue of $37.9M (+117.2% Y/Y) beats by $16.1M . Press Release More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Alnylam Pharmaceuticals beats by $0.19, beats on revenue

via: SeekingAlpha at 2018-02-08 08:01:32:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q4 EPS of -$1.20 beats by $0.19 . Revenue of $37.9M (+117.2% Y/Y) beats by $16.1M . Press Release More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity

via: Business Wire at 2018-02-08 08:00:00:000

Reported Final Results from APOLLO Phase 3 Study and Completed Filings of New Drug Application (NDA) and Marketing Authorisation Application (MAA) for Patisiran, with an Expected Commercial Launch in U.S. and Europe in Mid- and Late 2018, Respectively Advance… read more...

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity

via: Business Wire at 2018-02-08 08:00:00:000

Reported Final Results from APOLLO Phase 3 Study and Completed Filings of New Drug Application (NDA) and Marketing Authorisation Application (MAA) for Patisiran, with an Expected Commercial Launch in U.S. and Europe in Mid- and Late 2018, Respectively Advance… read more...

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity

via: Business Wire at 2018-02-08 08:00:00:000

Reported Final Results from APOLLO Phase 3 Study and Completed Filings of New Drug Application (NDA) and Marketing Authorisation Application (MAA) for Patisiran, with an Expected Commercial Launch in U.S. and Europe in Mid- and Late 2018, Respectively Advance… read more...

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity

via: Business Wire at 2018-02-08 08:00:00:000

Reported Final Results from APOLLO Phase 3 Study and Completed Filings of New Drug Application (NDA) and Marketing Authorisation Application (MAA) for Patisiran, with an Expected Commercial Launch in U.S. and Europe in Mid- and Late 2018, Respectively Advance… read more...

Notable earnings before Thursday's open

via: SeekingAlpha at 2018-02-07 17:30:01:000

ABB , ALNY , ALXN , BCE , BR , BWA , CAH , CBG , CBM , COR , COTY , CVS , EPC , FAF , GLPI , GOOS , GPI , GRA , GRUB , GT , GWR , HBI , K , KKR , LCII , MANU , MAS , MD , MDSO , MLCO , MMS , MMYT , MPW , NJR , NLSN , NS , NYT , ODFL , PAG , PENN , PM… read more...

Notable earnings before Thursday's open

via: SeekingAlpha at 2018-02-07 17:30:01:000

ABB , ALNY , ALXN , BCE , BR , BWA , CAH , CBG , CBM , COR , COTY , CVS , EPC , FAF , GLPI , GOOS , GPI , GRA , GRUB , GT , GWR , HBI , K , KKR , LCII , MANU , MAS , MD , MDSO , MLCO , MMS , MMYT , MPW , NJR , NLSN , NS , NYT , ODFL , PAG , PENN , PM… read more...

Notable earnings before Thursday's open

via: SeekingAlpha at 2018-02-07 17:30:01:000

ABB , ALNY , ALXN , BCE , BR , BWA , CAH , CBG , CBM , COR , COTY , CVS , EPC , FAF , GLPI , GOOS , GPI , GRA , GRUB , GT , GWR , HBI , K , KKR , LCII , MANU , MAS , MD , MDSO , MLCO , MMS , MMYT , MPW , NJR , NLSN , NS , NYT , ODFL , PAG , PENN , PM… read more...

Alnylam to Webcast Presentations at Upcoming February Investor Conferences

via: Business Wire at 2018-02-05 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 20 th Annual BIO CEO & Investor Conference on Monday, February 12, 2018 at 10:45 am ET at the Marriot… read more...

3 Things In Biotech You Should Learn Today: February 3, 2018

via: SeekingAlpha at 2018-02-04 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: February 3, 2018

via: SeekingAlpha at 2018-02-04 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

Ionis: Good Value With Non-Binary Upside

via: SeekingAlpha at 2018-02-02 11:59:15:000

Antisense Technology Ionis ( IONS ) is considered to be one of the leaders in discovering and developing RNA-targeted therapeutics. Ionis has created a broadly applicable drug discovery antisense technology platform to develop a large, diverse, and advanced pipeline of potentially first-in… read more...

Ionis: Good Value With Non-Binary Upside

via: SeekingAlpha at 2018-02-02 11:59:15:000

Antisense Technology Ionis ( IONS ) is considered to be one of the leaders in discovering and developing RNA-targeted therapeutics. Ionis has created a broadly applicable drug discovery antisense technology platform to develop a large, diverse, and advanced pipeline of potentially first-in… read more...

Ionis: Good Value With Non-Binary Upside

via: SeekingAlpha at 2018-02-02 11:59:15:000

Antisense Technology Ionis ( IONS ) is considered to be one of the leaders in discovering and developing RNA-targeted therapeutics. Ionis has created a broadly applicable drug discovery antisense technology platform to develop a large, diverse, and advanced pipeline of potentially first-in… read more...

Ionis: Good Value With Non-Binary Upside

via: SeekingAlpha at 2018-02-02 11:59:15:000

Antisense Technology Ionis ( IONS ) is considered to be one of the leaders in discovering and developing RNA-targeted therapeutics. Ionis has created a broadly applicable drug discovery antisense technology platform to develop a large, diverse, and advanced pipeline of potentially first-in… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018

via: SeekingAlpha at 2018-02-02 06:43:19:000

Market and sector outlook: No change in the bullish near-term outlook on S&P 500 index ( SPY ) from yesterday. The market Buy signal using VIX indicator continues. We expect Nasdaq Biotechnology Index ( IBB ) to also recover and make new highs. Up on >5x volume (excluding pen… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018

via: SeekingAlpha at 2018-02-02 06:43:19:000

Market and sector outlook: No change in the bullish near-term outlook on S&P 500 index ( SPY ) from yesterday. The market Buy signal using VIX indicator continues. We expect Nasdaq Biotechnology Index ( IBB ) to also recover and make new highs. Up on >5x volume (excluding pen… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018

via: SeekingAlpha at 2018-02-02 06:43:19:000

Market and sector outlook: No change in the bullish near-term outlook on S&P 500 index ( SPY ) from yesterday. The market Buy signal using VIX indicator continues. We expect Nasdaq Biotechnology Index ( IBB ) to also recover and make new highs. Up on >5x volume (excluding pen… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018

via: SeekingAlpha at 2018-02-02 06:43:19:000

Market and sector outlook: No change in the bullish near-term outlook on S&P 500 index ( SPY ) from yesterday. The market Buy signal using VIX indicator continues. We expect Nasdaq Biotechnology Index ( IBB ) to also recover and make new highs. Up on >5x volume (excluding pen… read more...

FDA accepts Alnylam's patisiran NDA for hATTR amyloidosis, action date August 11

via: SeekingAlpha at 2018-02-01 16:20:25:000

The FDA accepts for review Alnylam Pharmaceuticals' (NASDAQ: ALNY ) marketing application seeking approval for patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis. The agency's action date is August 11 under Priority Review status. More news on: Alnylam Pharmaceuticals, In… read more...

FDA accepts Alnylam's patisiran NDA for hATTR amyloidosis, action date August 11

via: SeekingAlpha at 2018-02-01 16:20:25:000

The FDA accepts for review Alnylam Pharmaceuticals' (NASDAQ: ALNY ) marketing application seeking approval for patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis. The agency's action date is August 11 under Priority Review status. More news on: Alnylam Pharmaceuticals, In… read more...

FDA accepts Alnylam's patisiran NDA for hATTR amyloidosis, action date August 11

via: SeekingAlpha at 2018-02-01 16:20:25:000

The FDA accepts for review Alnylam Pharmaceuticals' (NASDAQ: ALNY ) marketing application seeking approval for patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis. The agency's action date is August 11 under Priority Review status. More news on: Alnylam Pharmaceuticals, In… read more...

Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis

via: Business Wire at 2018-02-01 16:00:00:000

PDUFA date set for August 11, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for patisiran, an inve… read more...

Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis

via: Business Wire at 2018-02-01 16:00:00:000

PDUFA date set for August 11, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for patisiran, an inve… read more...

Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis

via: Business Wire at 2018-02-01 16:00:00:000

PDUFA date set for August 11, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for patisiran, an inve… read more...

Miragen Therapeutics May Provide Long Term Alpha Within The RNA Space

via: SeekingAlpha at 2018-02-01 10:49:29:000

Written by Dan Cohen and Scott Matusow Recently, we had a conference call with a Miragen Therapeutics ( MGEN ) , and left the call impressed with what we heard. CEO Bill Marshall was frank and to-the-point, and was able to answer all of our questions regarding the science and busine… read more...

Miragen Therapeutics May Provide Long Term Alpha Within The RNA Space

via: SeekingAlpha at 2018-02-01 10:49:29:000

Written by Dan Cohen and Scott Matusow Recently, we had a conference call with a Miragen Therapeutics ( MGEN ) , and left the call impressed with what we heard. CEO Bill Marshall was frank and to-the-point, and was able to answer all of our questions regarding the science and busine… read more...

Miragen Therapeutics May Provide Long Term Alpha Within The RNA Space

via: SeekingAlpha at 2018-02-01 10:49:29:000

Written by Dan Cohen and Scott Matusow Recently, we had a conference call with a Miragen Therapeutics ( MGEN ) , and left the call impressed with what we heard. CEO Bill Marshall was frank and to-the-point, and was able to answer all of our questions regarding the science and busine… read more...

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results

via: Business Wire at 2018-02-01 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2017 on Thursday, February 8, 2018, before the U.S. financial markets open. Management will pro… read more...

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results

via: Business Wire at 2018-02-01 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2017 on Thursday, February 8, 2018, before the U.S. financial markets open. Management will pro… read more...

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results

via: Business Wire at 2018-02-01 07:00:00:000

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2017 on Thursday, February 8, 2018, before the U.S. financial markets open. Management will pro… read more...

Sanofi Scoops Up Ablynx: Start Of A Buyout Spree?

via: SeekingAlpha at 2018-01-31 03:09:26:000

Ablynx ( ABLX ) has become the latest takeover success story, with drug giant Sanofi ( SNY ) offering $4.8 billion in cash for the Belgian biotech. Sanofis bid far outstrips that of Novo Nordisk ( NVO ), which had offered $3.1 billion earlier this month. Sanofi has been adding to… read more...

Sanofi Scoops Up Ablynx: Start Of A Buyout Spree?

via: SeekingAlpha at 2018-01-31 03:09:26:000

Ablynx ( ABLX ) has become the latest takeover success story, with drug giant Sanofi ( SNY ) offering $4.8 billion in cash for the Belgian biotech. Sanofis bid far outstrips that of Novo Nordisk ( NVO ), which had offered $3.1 billion earlier this month. Sanofi has been adding to… read more...

Sanofi Scoops Up Ablynx: Start Of A Buyout Spree?

via: SeekingAlpha at 2018-01-31 03:09:26:000

Ablynx ( ABLX ) has become the latest takeover success story, with drug giant Sanofi ( SNY ) offering $4.8 billion in cash for the Belgian biotech. Sanofis bid far outstrips that of Novo Nordisk ( NVO ), which had offered $3.1 billion earlier this month. Sanofi has been adding to… read more...

Your Daily Pharma Scoop: Sanofi To Acquire Ablynx, PTC Therapeutics Announces Data, Lutathera Approved

via: SeekingAlpha at 2018-01-30 08:00:00:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss Sanofis ( SNY ) takeover offer for Belgian biotech Ablynx ( ABLYF ). Ablyx had earlier this month rejected a hostile takeover offer from Novo Nordisk ( NVO ), noting that euro 30.50 per share offer undervalued … read more...

Your Daily Pharma Scoop: Sanofi To Acquire Ablynx, PTC Therapeutics Announces Data, Lutathera Approved

via: SeekingAlpha at 2018-01-30 08:00:00:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss Sanofis ( SNY ) takeover offer for Belgian biotech Ablynx ( ABLYF ). Ablyx had earlier this month rejected a hostile takeover offer from Novo Nordisk ( NVO ), noting that euro 30.50 per share offer undervalued … read more...

Your Daily Pharma Scoop: Sanofi To Acquire Ablynx, PTC Therapeutics Announces Data, Lutathera Approved

via: SeekingAlpha at 2018-01-30 08:00:00:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss Sanofis ( SNY ) takeover offer for Belgian biotech Ablynx ( ABLYF ). Ablyx had earlier this month rejected a hostile takeover offer from Novo Nordisk ( NVO ), noting that euro 30.50 per share offer undervalued … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

European marketing application for Alnylam's patisiran accepted for review, action date late June

via: SeekingAlpha at 2018-01-25 16:16:08:000

The European Medicines Agency (EMA) accepts for review Alnylam Pharmaceuticals' (NASDAQ: ALNY ) marketing application seeking approval for patisiran for the treatment of hereditary ATTR amyloidosis. Under previously granted accelerated assessment, the agency's action date is about June 24…. read more...

European marketing application for Alnylam's patisiran accepted for review, action date late June

via: SeekingAlpha at 2018-01-25 16:16:08:000

The European Medicines Agency (EMA) accepts for review Alnylam Pharmaceuticals' (NASDAQ: ALNY ) marketing application seeking approval for patisiran for the treatment of hereditary ATTR amyloidosis. Under previously granted accelerated assessment, the agency's action date is about June 24…. read more...

Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis

via: Business Wire at 2018-01-25 16:00:00:000

EMA Will Evaluate MAA Under Accelerated Assessment Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) and initiated… read more...

Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis

via: Business Wire at 2018-01-25 16:00:00:000

EMA Will Evaluate MAA Under Accelerated Assessment Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) and initiated… read more...

Sanofi: What To Think About The Bioverativ Acquisition?

via: SeekingAlpha at 2018-01-24 15:23:03:000

On January 22nd, Sanofi ( SNY ) has announced the acquisition of Bioverativ ( BIVV ) for $ 11.6B in cash ( 9.5B). The deal price represents a 64% premium to the previous day's closing price. A quick overview of Bioverativ Bioverativ (spun off from Biogen ( BIIB )) is a US biotech c… read more...

Ionis Pharmaceuticals Is Poised To Disrupt Biotech

via: SeekingAlpha at 2018-01-23 21:11:37:000

I have written this article with the layperson in mind, but I will try to stay true to the underlying science. Targeting the "undruggable" The general mantra of traditional biopharmaceuticals is to develop chemical-based drugs that affect a particular protein, altering a disease process… read more...

The Medicines Co's inclisiran an Orphan Drug in U.S. for HoFH; shares up 3%

via: SeekingAlpha at 2018-01-23 12:22:07:000

The FDA designates The Medicines Company's ( MDCO +2.5% ) inclisiran an Orphan Drug for the treatment of homozygous familial hypercholesterolemia (HoFH), an inherited disorder characterized by extremely high levels of "bad" cholesterol in the blood. More news on: The Medicines Compan… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-19 07:23:23:000

Intellipharmaceutics (NASDAQ: IPCI ) initiated with Buy rating and $2.50 (213% upside) price target by H.C. Wainwright. More news on: IntelliPharmaCeutics International Inc, PLx Pharma, Vanda Pharmaceuticals Inc., Healthcare stocks news, Read more … read more...

Stocks To Watch: Guidance Updates All Around

via: SeekingAlpha at 2018-01-13 10:15:28:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Earnings season heats up this week with more big names likely to follow in the path… read more...

When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018

via: SeekingAlpha at 2018-01-10 09:15:19:000

Market Pulse The year 2017 will be remembered as the year when the Bulls Growled and the Bears Mooed. A year when stock market volatility for the first time ever subsided to a level below that of bonds. A year when the market refused to relent to the historical valuation templates and hand… read more...

Your Daily Pharma Scoop: Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides Update, Axsome Suffers Setback

via: SeekingAlpha at 2018-01-10 01:14:42:000

Analysis of top Seeking Alpha coverage: Aradigm Today we will discuss the much-anticipated FDA briefing documents for Aradaigms ( ARDM ) Linhaliq. The documents were made available today ahead of the Ad Com meeting on Thursday, January 11 th . Following the release of the docu… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX